CA2968135A1 - Combination therapy effective against microorganisms, including drug resistant microorganisms - Google Patents
Combination therapy effective against microorganisms, including drug resistant microorganisms Download PDFInfo
- Publication number
- CA2968135A1 CA2968135A1 CA2968135A CA2968135A CA2968135A1 CA 2968135 A1 CA2968135 A1 CA 2968135A1 CA 2968135 A CA2968135 A CA 2968135A CA 2968135 A CA2968135 A CA 2968135A CA 2968135 A1 CA2968135 A1 CA 2968135A1
- Authority
- CA
- Canada
- Prior art keywords
- fosfomycin
- composition
- diaminopyridine
- sulfonamide
- susceptible microorganism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 167
- 229940079593 drug Drugs 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 238000002648 combination therapy Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 275
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical class C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims abstract description 169
- 229960000308 fosfomycin Drugs 0.000 claims abstract description 165
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 claims abstract description 155
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 139
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 98
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 48
- 238000009472 formulation Methods 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims description 187
- 239000003795 chemical substances by application Substances 0.000 claims description 140
- 208000015181 infectious disease Diseases 0.000 claims description 105
- 230000002401 inhibitory effect Effects 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 50
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical group COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- 229960001082 trimethoprim Drugs 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 41
- 230000003115 biocidal effect Effects 0.000 claims description 37
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical group O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 37
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 36
- 241000588724 Escherichia coli Species 0.000 claims description 29
- 230000002147 killing effect Effects 0.000 claims description 29
- 150000002148 esters Chemical class 0.000 claims description 27
- 239000003242 anti bacterial agent Substances 0.000 claims description 26
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims description 24
- 229960000611 pyrimethamine Drugs 0.000 claims description 24
- 208000035143 Bacterial infection Diseases 0.000 claims description 21
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 241000191967 Staphylococcus aureus Species 0.000 claims description 16
- 239000004599 antimicrobial Substances 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 229940023064 escherichia coli Drugs 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 230000004260 plant-type cell wall biogenesis Effects 0.000 claims description 12
- 238000009635 antibiotic susceptibility testing Methods 0.000 claims description 10
- 206010040872 skin infection Diseases 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 10
- 206010017964 Gastrointestinal infection Diseases 0.000 claims description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 9
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 9
- 241000606768 Haemophilus influenzae Species 0.000 claims description 8
- HWJPWWYTGBZDEG-UHFFFAOYSA-N 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine Chemical compound C=12C=CC(C3CC3)OC2=C(OC)C(OC)=CC=1CC1=CN=C(N)N=C1N HWJPWWYTGBZDEG-UHFFFAOYSA-N 0.000 claims description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 7
- 241000588770 Proteus mirabilis Species 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960001925 iclaprim Drugs 0.000 claims description 7
- 208000032376 Lung infection Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 206010048038 Wound infection Diseases 0.000 claims description 6
- 239000003096 antiparasitic agent Substances 0.000 claims description 6
- 229940125687 antiparasitic agent Drugs 0.000 claims description 6
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 208000019206 urinary tract infection Diseases 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 108010022394 Threonine synthase Proteins 0.000 claims description 5
- 208000019836 digestive system infectious disease Diseases 0.000 claims description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 241000589242 Legionella pneumophila Species 0.000 claims description 4
- 241000588772 Morganella morganii Species 0.000 claims description 4
- 241000588767 Proteus vulgaris Species 0.000 claims description 4
- 229960004755 ceftriaxone Drugs 0.000 claims description 4
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 229940115932 legionella pneumophila Drugs 0.000 claims description 4
- 229940076266 morganella morganii Drugs 0.000 claims description 4
- 229940007042 proteus vulgaris Drugs 0.000 claims description 4
- 206010056519 Abdominal infection Diseases 0.000 claims description 3
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 3
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 3
- 241001453380 Burkholderia Species 0.000 claims description 3
- 241000588697 Enterobacter cloacae Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
- 241000588774 Providencia sp. Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940065181 bacillus anthracis Drugs 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229960003085 meticillin Drugs 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 230000009798 acute exacerbation Effects 0.000 claims description 2
- 244000045947 parasite Species 0.000 abstract description 18
- 230000000694 effects Effects 0.000 description 44
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 41
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 35
- 229940047766 co-trimoxazole Drugs 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- 230000001580 bacterial effect Effects 0.000 description 31
- 239000000651 prodrug Substances 0.000 description 23
- 229940002612 prodrug Drugs 0.000 description 23
- 230000000844 anti-bacterial effect Effects 0.000 description 20
- -1 analogs Chemical class 0.000 description 19
- 238000003556 assay Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 229940088710 antibiotic agent Drugs 0.000 description 16
- 230000002195 synergetic effect Effects 0.000 description 16
- 230000037361 pathway Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 241000194032 Enterococcus faecalis Species 0.000 description 12
- 241000192125 Firmicutes Species 0.000 description 12
- 238000010611 checkerboard assay Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 229940032049 enterococcus faecalis Drugs 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 7
- 208000030852 Parasitic disease Diseases 0.000 description 7
- 108010013639 Peptidoglycan Proteins 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 238000002815 broth microdilution Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 238000002814 agar dilution Methods 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 230000000869 mutational effect Effects 0.000 description 5
- 229960000564 nitrofurantoin Drugs 0.000 description 5
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 5
- 206010061182 Genitourinary tract infection Diseases 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241000588914 Enterobacter Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000010610 time kill assay Methods 0.000 description 3
- 239000006150 trypticase soy agar Substances 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 description 2
- MTERSQYMYBGZTP-UHFFFAOYSA-N 4-amino-n-(5-methyl-2-phenylpyrazol-3-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1N1N=C(C)C=C1NS(=O)(=O)C1=CC=C(N)C=C1 MTERSQYMYBGZTP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000991060 Homo sapiens MHC class I polypeptide-related sequence A Proteins 0.000 description 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 2
- RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 description 2
- 108010079780 Pristinamycin Proteins 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- BFCRRLMMHNLSCP-UHFFFAOYSA-N brodimoprim Chemical compound COC1=C(Br)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 BFCRRLMMHNLSCP-UHFFFAOYSA-N 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229950006412 delafloxacin Drugs 0.000 description 2
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960003961 pristinamycin Drugs 0.000 description 2
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 2
- JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229950008588 solithromycin Drugs 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 2
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 2
- 229960004936 sulfamethoxypyridazine Drugs 0.000 description 2
- 229960002229 sulfametoxydiazine Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- RVCQIPMAVHATKD-UHFFFAOYSA-N 3,4-diaminopyridine-2-sulfonamide Chemical compound NC1=CC=NC(S(N)(=O)=O)=C1N RVCQIPMAVHATKD-UHFFFAOYSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- DAUFGBIKKGOPJA-UHFFFAOYSA-N 4-amino-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound CC1=C(C)ON=C1NS(=O)(=O)C1=CC=C(N)C=C1 DAUFGBIKKGOPJA-UHFFFAOYSA-N 0.000 description 1
- YEAICDDXRUOCKJ-UHFFFAOYSA-N 4-amino-n-pyrazin-2-ylbenzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=CC=N1 YEAICDDXRUOCKJ-UHFFFAOYSA-N 0.000 description 1
- HRZQMMXCASMDBP-UHFFFAOYSA-N 5-[(3,5-dimethoxy-4-methylsulfanylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound COC1=C(SC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 HRZQMMXCASMDBP-UHFFFAOYSA-N 0.000 description 1
- WTIRTQHTGPHRMQ-UHFFFAOYSA-N 5-[(4-amino-3,5-dichlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1CC1=CC(Cl)=C(N)C(Cl)=C1 WTIRTQHTGPHRMQ-UHFFFAOYSA-N 0.000 description 1
- DFHRMBQNMXVPJF-UHFFFAOYSA-N 5-[[3,5-dichloro-4-(dimethylamino)phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1=C(Cl)C(N(C)C)=C(Cl)C=C1CC1=CN=C(N)N=C1N DFHRMBQNMXVPJF-UHFFFAOYSA-N 0.000 description 1
- SUMDGVMLMLBYIZ-UHFFFAOYSA-N 5-[[3,5-dichloro-4-(ethylamino)phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1=C(Cl)C(NCC)=C(Cl)C=C1CC1=CN=C(N)N=C1N SUMDGVMLMLBYIZ-UHFFFAOYSA-N 0.000 description 1
- QXPMGNMUZSEBMW-UHFFFAOYSA-N 5-[[3,5-dichloro-4-(methylamino)phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1=C(Cl)C(NC)=C(Cl)C=C1CC1=CN=C(N)N=C1N QXPMGNMUZSEBMW-UHFFFAOYSA-N 0.000 description 1
- XHPZVBGIPQQTQW-UHFFFAOYSA-N 5-benzylpyrimidine-2,4-diamine Chemical class NC1=NC(N)=NC=C1CC1=CC=CC=C1 XHPZVBGIPQQTQW-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588754 Klebsiella sp. Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000206591 Peptococcus Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000252 brodimoprim Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- YMZJBJPWTXJQMR-MUWMCQJSSA-L calcium;[(2s,3r)-3-methyloxiran-2-yl]-dioxido-oxo-$l^{5}-phosphane Chemical group [Ca+2].C[C@H]1O[C@H]1P([O-])([O-])=O YMZJBJPWTXJQMR-MUWMCQJSSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LDBTVAXGKYIFHO-UHFFFAOYSA-N diaveridine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=CN=C(N)N=C1N LDBTVAXGKYIFHO-UHFFFAOYSA-N 0.000 description 1
- 229950000246 diaveridine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 229950008901 metioprim Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003007 phosphonic acid derivatives Chemical class 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- XOXHILFPRYWFOD-UHFFFAOYSA-N sulfachloropyridazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=C(Cl)N=N1 XOXHILFPRYWFOD-UHFFFAOYSA-N 0.000 description 1
- 229950008831 sulfachlorpyridazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 description 1
- 229960004257 sulfaguanidine Drugs 0.000 description 1
- 229960000468 sulfalene Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- 229960001969 sulfametrole Drugs 0.000 description 1
- IZOYMGQQVNAMHS-UHFFFAOYSA-N sulfametrole Chemical compound COC1=NSN=C1NS(=O)(=O)C1=CC=C(N)C=C1 IZOYMGQQVNAMHS-UHFFFAOYSA-N 0.000 description 1
- 229960001363 sulfamoxole Drugs 0.000 description 1
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- 229950003013 sulfapyrazole Drugs 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 229960003097 sulfaquinoxaline Drugs 0.000 description 1
- ZQMQGBHQZZQTJE-UHFFFAOYSA-N sulfasymazine Chemical compound CCC1=NC(CC)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZQMQGBHQZZQTJE-UHFFFAOYSA-N 0.000 description 1
- 229950003748 sulfasymazine Drugs 0.000 description 1
- 229950007264 sulfatroxazole Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- WSWJIZXMAUYHOE-UHFFFAOYSA-N tetroxoprim Chemical compound C1=C(OC)C(OCCOC)=C(OC)C=C1CC1=CN=C(N)N=C1N WSWJIZXMAUYHOE-UHFFFAOYSA-N 0.000 description 1
- 229960004809 tetroxoprim Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria. These novel compositions are also effective against microorganisms or strains thereof now susceptible to the combination even though said microorganisms or strains thereof were previously found or were considered resistant or intolerant to at least one of the components of the novel composition, when the at least one component was used alone at what was considered an effective dosing amount or concentration.
Description
2 TITLE
[0001]
COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG
RESISTANT MICROORGANISMS
CROSS REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application Number 62/081,394, filed on November 18, 2014, and to U.S. Provisional Patent Application Number 62/104,805, filed on January 18, 2015, and to U.S. Provisional Patent Application Number 62/245,095, filed on October 22, 2015, all of which are hereby incorporated by reference in their entirety, and to the maximum extent allowable by law.
FIELD OF THE INVENTION
[0001]
COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG
RESISTANT MICROORGANISMS
CROSS REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application Number 62/081,394, filed on November 18, 2014, and to U.S. Provisional Patent Application Number 62/104,805, filed on January 18, 2015, and to U.S. Provisional Patent Application Number 62/245,095, filed on October 22, 2015, all of which are hereby incorporated by reference in their entirety, and to the maximum extent allowable by law.
FIELD OF THE INVENTION
[0003] The subject application describes novel compositions provided as pharmaceutical compositions comprising a combination having unexpectedly high synergistic activity against microorganisms, including both Gram negative and Gram positive bacteria, and drug resistant strains of bacteria, as well as parasites. Unpredictably, said compositions are also effective against bacteria and/or parasites that are resistant to one or more compounds contained in the combination.
BACKGROUND
BACKGROUND
[0004]
Resistance of a microorganism to a pharmaceutical antibiotic typically leads to a decline in efficacy of said antibiotic. It also, as expected, leads to a decline in use of said antibiotic against the resistant microorganisms. Some antibiotics for which resistant strains have developed remain in use against mild to moderate infections. Said antibiotics are not often acceptable or effective for use against severe infections, or hospital-acquired infections, including infections to which one or more antibiotics are resistant.
Resistance of a microorganism to a pharmaceutical antibiotic typically leads to a decline in efficacy of said antibiotic. It also, as expected, leads to a decline in use of said antibiotic against the resistant microorganisms. Some antibiotics for which resistant strains have developed remain in use against mild to moderate infections. Said antibiotics are not often acceptable or effective for use against severe infections, or hospital-acquired infections, including infections to which one or more antibiotics are resistant.
[0005] There remains a need for effective compositions, and therapies that have activity not only against microorganisms that cause or contribute to mild to moderate infections, but are also effective, and provide sustained activity, and effectiveness, against microorganisms that cause or contribute to severe infections, including infections developed by resistant strains of Gram negative or Gram positive bacteria, or developed from or contributed by parasites.
These and other needs are met by the compositions described below.
SUMMARY
These and other needs are met by the compositions described below.
SUMMARY
[0006]
Described herein are novel compositions and uses for said novel compositions.
Said compositions overcome one or more of the above described problems or obstacles. For example, the described novel compositions effectively kill microorganisms, including bacteria, and/or inhibit growth of said microorganisms, including bacteria, and/or drug-resistant bacteria, and/or multi-drug resistant bacteria, and/or parasites, and/or drug-resistant parasites.
Described herein are novel compositions and uses for said novel compositions.
Said compositions overcome one or more of the above described problems or obstacles. For example, the described novel compositions effectively kill microorganisms, including bacteria, and/or inhibit growth of said microorganisms, including bacteria, and/or drug-resistant bacteria, and/or multi-drug resistant bacteria, and/or parasites, and/or drug-resistant parasites.
[0007] The novel compositions have broad spectrum activity, including activity against both Gram-positive bacteria (e.g., Staphylococci, Enterococci, Streptococci, Clostridia) and Gram-negative bacteria (e.g., E. coli, H. influenzae, and other Enterobacteriaceae, Pseudomonas aeruginosa, Proteus mirabilis, and Neisseria gonorrhoeae). The broad spectrum activity includes activity against drug-resistant bacteria. The bacteria may be a multi-drug resistant bacteria, or a pan-resistant bacteria.
The activity may include parasites. The microorganisms (e.g., bacteria and/or parasites) are those susceptible to one or more of the components of the compositions described herein.
The activity may include parasites. The microorganisms (e.g., bacteria and/or parasites) are those susceptible to one or more of the components of the compositions described herein.
[0008] Said compositions include a combination of compounds or agents.
In some embodiments, when said composition (that includes the combination of compounds or agents) is provided to one or more susceptible microorganisms or to a subject indicated to contain or containing the one or more susceptible microorganisms, the combination of compounds or agents exhibit activity or a therapeutic effect with regard to the one or more susceptible microorganisms.
In some embodiments, when said composition (that includes the combination of compounds or agents) is provided to one or more susceptible microorganisms or to a subject indicated to contain or containing the one or more susceptible microorganisms, the combination of compounds or agents exhibit activity or a therapeutic effect with regard to the one or more susceptible microorganisms.
[0009] In some embodiments, when said composition (that includes the combination of compounds or agents) is provided to one or more susceptible microorganisms or to a subject indicated to contain or containing the one or more susceptible microorganisms, the combination of compounds or agents exhibit a synergistic effect with regard to the one or more susceptible microorganisms. The synergistic effect is considered an activity or therapeutic effect that is greater than the activity or therapeutic effect of said agents or compounds when used separately. As such, when provided as a combination of compounds or agents at least one of the compounds or agents in the combination, or more than one of the compounds or agents in the combination, may be provided at the same doses or at doses lower than used currently and/or effectively for each compound when provided separately. The same or lower doses for the combination described herein includes effective doses that are the same or are often lower than the current indications or recommendations for use of at least one of the independent compounds or agents utilized in the described combination. In some embodiments, when the composition described herein (the described combination of compounds or agents) is provided to one or more susceptible microorganisms or to a subject indicated to contain or containing the one or more susceptible microorganisms, the combination of compounds or agents described herein exhibit activity or a therapeutic effect with regard to the one or more susceptible microorganisms, at said doses that are the same or are lower based on current indications or recommendations for use of each independent compound or agent when used alone.
[0010] The compositions described herein and containing a combination of compounds may be provided to the one or more susceptible microorganisms, or to a subject indicated to contain or containing the one or more susceptible microorganisms, such that the composition is provided as the combination of compounds. The components of the combination (e.g., the compounds or agents) may be provided independently, provided sequentially, or provided concomitantly.
Providing concomitantly may include providing together, such as in a blend, mixture, or in a same dose or formulation.
Providing concomitantly may include providing simultaneously, or concurrently, or providing in parallel, such as at or about a same time or at or about a same schedule. In some embodiments, at least part of a daily dosing or administration schedule of the more than one compound or agent in the composition may overlap. On a same day, the more than one compound or agent of the combination may be provided independently and/or together.
Providing concomitantly may include providing together, such as in a blend, mixture, or in a same dose or formulation.
Providing concomitantly may include providing simultaneously, or concurrently, or providing in parallel, such as at or about a same time or at or about a same schedule. In some embodiments, at least part of a daily dosing or administration schedule of the more than one compound or agent in the composition may overlap. On a same day, the more than one compound or agent of the combination may be provided independently and/or together.
[0011] In one or more embodiments, a composition described herein includes a combination of two or more compounds or agents described herein, in which one of said compounds or agents is a combination of two independent compounds or components. Activity, and/or efficacy of such a composition may be comparable in activity, and/or efficacy with at least one of said agents or compounds when said one agent or compound is used separately. Activity, and/or efficacy of such a composition as described herein may be comparable in activity, and/or efficacy or provide better activity, and/or efficacy than the activity or therapeutic effect of each of the compounds or agent used alone, or when used in a manner currently prescribed for use of said independent compounds or agents (utilized as prescribed, and not in the combinations described herein).
[0012] In one or more embodiments, a composition described herein includes a combination of two or more compounds or agents described herein, in which one of said compounds or agents is a specific combination of two independent compounds or components, such that the activity, and/or efficacy of the composition (which is the combination of the two or more compounds or agents, in which one of said agents is the specific combination of two independent compounds or components) is not only greater than the activity or therapeutic effect of one of said agents or compounds when used separately, but is also greater than the activity or therapeutic effect of the specific combination of the two independent compounds or components as they may be prescribed for use as the specific combination.
[0013] In one or more embodiments, said compositions (comprising two or more compounds or agents) have unexpectedly been found to exhibit activity, and/or are effective against bacterial strains that are resistant to at least one of the two or more compounds or agents when the two or more compounds were tested separately. In one or more embodiments, said compositions (comprising two or more compounds or agents) have unexpectedly been found to exhibit activity, and/or are effective against bacterial strains that are resistant to each of the two or more compounds or agents when the two or more compounds were tested separately. In one or more embodiments, said compositions (comprising two or more compounds or agents) have unexpectedly been found to exhibit, activity and/or are effective against bacterial strains that are resistant to the specific combination of the two of the independent compounds or components typically used in combination. Heretofore, bacteria exhibiting resistance to a compound or agent, or to the specific combination of the two independent compounds or components typically used in the specific combination, have not been found to later be susceptible to said compound or agent, or to said specific combination of the two independent compounds or components used in the specific combination. Unexpectedly, however, when compositions are so combined as described herein, bacterial strains that were resistant to the separate compound or agent (and/or to the specific combination of the two independent compounds or components) are now susceptible to the novel compositions described herein that includes the specific combination of the two or more compounds or components.
[0014] In some embodiments, activity, and/or efficacy of the described novel compositions may be found to be better or far better than a four-fold reduction in the minimal inhibitory concentration (MIC) typically used to define synergy when assessed by a checkerboard microdilution assay. When the compositions described herein are provided to one or more target microorganisms having a diminished response to an alternative compound (e.g., exhibiting reduced susceptibility or exhibiting resistance to the alternative compound), the activity, and efficacy may be far better than would be expected with a simple additive response. In some embodiments, efficacy of the compositions described herein are far superior than expected, based on the efficacy of the two or more compounds or agents when used separately on the same microorganisms (e.g., same type of microorganisms).
[0015] In some embodiments, efficacy of the compositions described herein (which may include a first compound or agent, and a second compound or agent, the second compound including the specific combination of two independent components) are better or far better than when the first compound or agent or the second compound are used independently on the same microorganisms (e.g., same type of microorganisms). In some embodiments, the activity, and/or efficacy of the described compositions are far greater than would be predicted based on the activity, and/or efficacy of each individual compound on susceptible microorganisms. In some embodiments, the first compound is a first component or agent, and the second compound is a second component or agent. In some embodiments, the first compound is a first component or agent, and the second compound is a combination of two independent components or agents.
[0016]
Unexpectedly, and in some embodiments, the novel compositions described herein exhibit synergistic growth inhibition as well as bactericidal synergy W log10 change in viable count assessed by a minimal bactericidal concentration time-kill assay after 24 hours as compared with the compounds or agents used separately).
Unexpectedly, and in some embodiments, the novel compositions described herein exhibit synergistic growth inhibition as well as bactericidal synergy W log10 change in viable count assessed by a minimal bactericidal concentration time-kill assay after 24 hours as compared with the compounds or agents used separately).
[0017] In additional embodiments are compositions (comprising the two or more compounds or agents), and methods of use including methods for inhibiting or preventing growth of one or more microorganisms that were previously not considered susceptible to the two or more compounds or agents when used separately or as they are independently indicated for use.
[0018] Also described herein are compositions, and methods of use of said compositions, including methods for stopping further microbial growth, including methods for killing microbial cells. Methods may be performed in vivo, ex vivo, in vitro, in situ etc.
Methods described herein may be for killing or inhibiting further growth of one or more microorganism, including one or more drug resistant microorganisms, such as an antibiotic-resistant microorganism.
Methods described herein may be for killing or inhibiting further growth of one or more microorganism, including one or more drug resistant microorganisms, such as an antibiotic-resistant microorganism.
[0019] Still further are pharmaceutical compositions, and methods for treating an organism (multi-cellular) or mammal in need thereof, such as a mammal exhibiting susceptibility to or an infection from or considered to be due to one or more microorganisms. In some embodiments, said infection may be considered a severe infection. In some embodiments, said infection may include an infection requiring hospitalization. In some embodiments, said microorganisms may be one or more resistant strains of microorganisms, such as those considered antibiotic resistant. In some embodiments, methods described herein include treating at least one resistant strain of microorganism by administering, to a subject susceptible to, and/or exhibiting a possible infection or a known infection from the at least one resistant strain of the microorganism, a therapeutic dose of a composition described herein, one comprising a combination of two or more compounds or agents, each of the of two or more compounds or agents considered an antimicrobial agent on its own that could be provided to the patient independently. In some embodiments, the patient may have previously been found to be resistant to or less susceptible to one or all of the two or more compounds or agents when used indecently on the patient. In one or more embodiments, treating includes administering to a subject in need. Treatment may occur in an office, or a home, as suitable examples. In some embodiments, the treatment may be in a hospital, the subject having or exhibiting a serious or severe infection.
[0020] In some embodiments, pharmaceutical compositions, and methods are described herein for treating a drug-resistant microbial infection (e.g., an antibiotic-resistant microbial infection). The method comprises administering a therapeutic dose of a composition described herein, one comprising a combination of two or more compounds or agents, each of the of two or more compounds or agents considered an antimicrobial agent on its own.
[0021] Methods, and composition described herein may be particularly useful for treating infections that arose from one or more drug-resistant microorganisms.
[0022] The described compositions may also serve as compositions for sterilization, and/or to prevent contamination by one or more microorganisms, including microorganisms that may exhibit resistance to an antimicrobial. Methods for sterilization, and/or for preventing contamination include applying the described composition to the surface in need of sterilization or decontamination. The surface may be organic or inorganic, living or non-living, moveable or non-moveable, including surfaces at a facility, or on a structure, device, and/or equipment.
[0023] In some embodiments, any of the novel compositions may be further combined with another anti-infective agent or composition, such as another antibacterial agent or composition, or with an antiviral agent or composition, or with an antifungal agent or composition, or with an anti-parasitic agent or composition.
[0024] The novel compositions described herein may be provided in therapeutically acceptable doses for the treatment of one or more susceptible infections, including but not limited to respiratory tract, and/or lung infections, systemic infections, gastrointestinal infections, skin infections, and genitourinary tract infections.
[0025] The novel compositions described herein may be provided in therapeutically acceptable doses for the treatment of one or more susceptible infections, including but not limited to respiratory tract, and/or lung infections, systemic infections, gastrointestinal infections, skin infections, and genitourinary tract infections found resistant to one or more alternative antimicrobial drugs.
[0026] The novel compositions described herein may be provided in therapeutically acceptable doses for the treatment of one or more susceptible infections, including but not limited to respiratory tract, and/or lung infections, systemic infections, gastrointestinal infections, skin infections, and genitourinary tract infections found resistant to one or more of the components in the composition described herein (e.g., when said component was used alone at its therapeutically acceptable dose for treatment of said one or more infections).
[0027] The novel compositions described herein may also be provided in concentrated doses, in which one or all of said components of the novel compositions require at least one dilution prior to providing the novel composition for the treatment of one or more susceptible infections, including but not limited to respiratory tract, and/or lung infections, systemic infections, gastrointestinal infections, skin infections, and genitourinary tract infections.
[0028] The novel compositions described herein will be useful, such as in therapeutically acceptable doses, against at least one or more of the following microorganisms: Staphylococcus spp.
(e.g., methicillin-resistant Staphylococcus aureus (MRSA)), Streptococcus spp., Enterococcus spp., Bacillus anthracis, Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae, Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia spp., Acinetobacter baumanii, Proteus mirabilis, Proteus vulgaris, Providencia sp., Morganella morganii), Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, and Yersinia pestis.
Compositions described herein are also active against additional microorganisms, including but not limited to biowarfare agents, and bacterial strains resistant to other antibacterial classes including, for example, extended spectrum beta-lactamase, carbaepenemase producing E.
coli, and K.
pneumoniae, carbapenem-resistant, multidrug- or pan-resistant P. aeruginosa.
Said novel compositions may be used effectively in humans and in animals.
(e.g., methicillin-resistant Staphylococcus aureus (MRSA)), Streptococcus spp., Enterococcus spp., Bacillus anthracis, Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae, Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia spp., Acinetobacter baumanii, Proteus mirabilis, Proteus vulgaris, Providencia sp., Morganella morganii), Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, and Yersinia pestis.
Compositions described herein are also active against additional microorganisms, including but not limited to biowarfare agents, and bacterial strains resistant to other antibacterial classes including, for example, extended spectrum beta-lactamase, carbaepenemase producing E.
coli, and K.
pneumoniae, carbapenem-resistant, multidrug- or pan-resistant P. aeruginosa.
Said novel compositions may be used effectively in humans and in animals.
[0029] Novel compositions may comprise a therapeutically effective amount of the composition provided as an antimicrobial.
[0030] The novel compositions will include a combination of compounds or agents comprising at least a fosfomycin, or a suitable salt, analog, derivative, or prodrug thereof, any of which have inhibitory activity in cell wall (peptidoglycan) synthesis (e.g., inhibit MurA
or cell wall synthesis). The combination may further comprise one or more sulfonamide, including analogs, and derivatives thereof, any of which have inhibitory activity in the metabolism of folic acid. Additionally or alternatively, the combination may further comprise one or more diaminopyridine, including analogs, and derivatives thereof, any of which have inhibitory activity in the metabolism of folic acid.
The combination of described components may be provided in a form described herein for the treatment of one or more infections described above. The combination of described components may be provided in a form described herein for use with a microorganism susceptible to the novel composition. The combination of described components may be provided in a form described herein for use with a susceptible microorganism, in which a low MIC is found within the "susceptible" range. The combination of described components may be provided in a form described herein for the treatment of one or more bacterial infections. The combination of described components may be provided in a form described herein for the treatment of one or more complicated bacterial infections. The described novel compositions may further comprise an excipient. The one or more sulfonamide and the one or more diaminopyridine may be provided as a combination. Said combination of the sulfonamide to diaminopyridine may be in a ratio of between about 3:1 and about 6:1. Additional ranges may also be acceptable. Said combination of the sulfonamide to diaminopyridine may be in a ratio of between about 3:1 and about 19:1 (e.g., for Cmax).
or cell wall synthesis). The combination may further comprise one or more sulfonamide, including analogs, and derivatives thereof, any of which have inhibitory activity in the metabolism of folic acid. Additionally or alternatively, the combination may further comprise one or more diaminopyridine, including analogs, and derivatives thereof, any of which have inhibitory activity in the metabolism of folic acid.
The combination of described components may be provided in a form described herein for the treatment of one or more infections described above. The combination of described components may be provided in a form described herein for use with a microorganism susceptible to the novel composition. The combination of described components may be provided in a form described herein for use with a susceptible microorganism, in which a low MIC is found within the "susceptible" range. The combination of described components may be provided in a form described herein for the treatment of one or more bacterial infections. The combination of described components may be provided in a form described herein for the treatment of one or more complicated bacterial infections. The described novel compositions may further comprise an excipient. The one or more sulfonamide and the one or more diaminopyridine may be provided as a combination. Said combination of the sulfonamide to diaminopyridine may be in a ratio of between about 3:1 and about 6:1. Additional ranges may also be acceptable. Said combination of the sulfonamide to diaminopyridine may be in a ratio of between about 3:1 and about 19:1 (e.g., for Cmax).
[0031] The described novel compositions may be administered to a subject in need thereof.
The described novel compositions may be administered in addition to one or more of another agent selected from the group consisting of antibiotic, antiviral agent, antifungal agent, anti-parasitic agent, and combinations thereof. Each described novel composition is effective at killing or inhibiting growth of a bacteria and/or parasite or other microorganism considered to be involved or responsible for the one or more infections described above. The bacteria may be a Gram positive bacteria involved or responsible for the one or more infections described above. The bacteria may be a Gram negative bacteria involved or responsible for the one or more infections described above.
The bacteria may be any one or more of a group of Gram positive bacteria. The bacteria may be any one or more of a group of Gram negative bacteria. The bacteria may be a combination of one or more Gram positive bacteria and one or more Gram negative bacteria.
Representative bacteria include but are not limited to Staphylococcus spp., including methicillin-resistant Staphylococcus aureus, Streptococcus spp., Enterococcus spp., Bacillus anthracis, Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae, Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia spp., Acinetobacter bauman ii, Proteus mirabilis, Proteus vulgaris, Providencia sp., and Morganella morganii, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, and Yersinia pestis.
The described novel compositions may be administered in addition to one or more of another agent selected from the group consisting of antibiotic, antiviral agent, antifungal agent, anti-parasitic agent, and combinations thereof. Each described novel composition is effective at killing or inhibiting growth of a bacteria and/or parasite or other microorganism considered to be involved or responsible for the one or more infections described above. The bacteria may be a Gram positive bacteria involved or responsible for the one or more infections described above. The bacteria may be a Gram negative bacteria involved or responsible for the one or more infections described above.
The bacteria may be any one or more of a group of Gram positive bacteria. The bacteria may be any one or more of a group of Gram negative bacteria. The bacteria may be a combination of one or more Gram positive bacteria and one or more Gram negative bacteria.
Representative bacteria include but are not limited to Staphylococcus spp., including methicillin-resistant Staphylococcus aureus, Streptococcus spp., Enterococcus spp., Bacillus anthracis, Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae, Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia spp., Acinetobacter bauman ii, Proteus mirabilis, Proteus vulgaris, Providencia sp., and Morganella morganii, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, and Yersinia pestis.
[0032] In additional embodiments are pharmaceutical compositions suitable for killing a microorganism in a subject in need thereof, the composition comprising a fosfomycin, and one or more of at least one sulfonamide, and/or at least one diaminopyridine. The pharmaceutical compositions may be provided for treatment of one or more bacterial infection or parasitic infection, including but not limited to those described above. The pharmaceutical compositions may be provided for prevention of one or more bacterial infection or parasitic infection. The pharmaceutical compositions may be provided for prevention or treatment of one or more complicated infections. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including analogs, and derivatives thereof. Components of the pharmaceutical composition may be in separable forms, or a premix form, or some combination thereof.
[0033] In additional embodiments are antimicrobial pharmaceutical compositions suitable for parenteral injection comprising two or more of a fosfomycin, a sulfamethoxazole; and a trimethoprim. The combination of agents may be provided for the treatment of one or more bacterial infections described above. The combination of agents may be provided for the treatment of one or more complicated bacterial infections. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including an analog, and derivative thereof. Components of the antimicrobial pharmaceutical composition may be in separable forms or a premix form or some combination thereof.
[0034] In further embodiments are antimicrobial pharmaceutical compositions suitable for oral administration comprising two or more of a fosfomycin, a sulfamethoxazole; and a trimethoprim.
The combination of agents may be provided for the treatment of one or more infections described above. The combination of agents may be provided for the treatment of one or more uncomplicated infections. The combination of agents may be provided for the treatment of one or more complicated infections. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including an analog, and derivative thereof.
Components of the antimicrobial pharmaceutical composition may be in separable forms or a premix form or some combination thereof.
The combination of agents may be provided for the treatment of one or more infections described above. The combination of agents may be provided for the treatment of one or more uncomplicated infections. The combination of agents may be provided for the treatment of one or more complicated infections. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including an analog, and derivative thereof.
Components of the antimicrobial pharmaceutical composition may be in separable forms or a premix form or some combination thereof.
[0035] In further embodiments are antimicrobial pharmaceutical compositions suitable for inhalation comprising two or more of a fosfomycin, a sulfamethoxazole; and a trimethoprim. The combination of agents may be provided for the treatment of one or more infections described above. The combination of agents may be provided for the treatment of one or more uncomplicated infections. The combination of agents may be provided for the treatment of one or more complicated infections. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including an analog, and derivative thereof.
Components of the antimicrobial pharmaceutical composition may be in separable forms or a premix form or some combination thereof.
Components of the antimicrobial pharmaceutical composition may be in separable forms or a premix form or some combination thereof.
[0036] The above described antimicrobial pharmaceutical compositions may be active against at least one of the group consisting of complicated urinary tract infections, complicated respiratory tract infections, including lung infections associated with cystic fibrosis, hospital acquired bacterial pneumonia, acute exacerbation of bronchitis associated with chronic obstructive pulmonary disease, ceftriaxone resistant infections, and drug-resistant abdominal infections.
[0037] With the compositions described herein are methods of inhibiting growth, or of killing a microorganism, including a Gram-positive bacteria, a Gram-negative bacteria, a parasite, a drug-resistant bacteria, and/or a drug-resistant parasite. One representative method comprises providing a therapeutically effective amount of a composition described herein to the microorganism, the composition comprising a combination of agents, the combination of agents comprising at least a fosfomycin, and one or more of at least one sulfonamide, and/or one or more of at least one diaminopyridine, said combination inhibiting growth of the microorganism, or killing the microorganism. The therapeutically effective amount of the composition described herein may increase the area under the concentration curve (AUC) of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, upon administration, as compared with an individual administration of any one of the fosfomycin, the sulfonamide, and the diaminopyridine when administered alone. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, or an analog, or derivative thereof, any of which have inhibitory activity in cell wall biosynthesis (e.g., inhibit peptidoglycan synthesis, MurA synthesis). The at least one sulfonamide may include an analog, or derivative thereof, any of which have inhibitory activity in the synthesis of dihydrofolate, or is sulfamethoxazole. The at least one diaminopyridine may include an analog, or derivative thereof, any of which inhibit dihydrofolate reductase, or is trimethoprim, or is pyrimethamine. The microorganism may be a bacteria. The microorganism may be a parasite. The microorganism may be one suspected of causing a bacterial infection and/or parasitic infection, such as described above, or selected from one or more in the group including, but not limited, to gastrointestinal infection, genitourinary infection, respiratory infection, a skin infection, a systemic infection, a wound infection, a sexually transmitted infection, or sexually transmitted infection disease. The microorganism may be resistant to one or more antibacterial agents. The microorganism may be resistant to one or more antiparasitic agents. The microorganism may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The microorganism may reside in a subject. The subject may be any of a human, and an animal and has a condition associated with or indicating an infection from the microorganism.
The infection may be mild, moderate or severe. The infection may be a gastrointestinal infection, urogenital infection, respiratory infection, a skin infection, a systemic infection, a wound infection, and/or a sexually transmitted disease. The microorganism may reside in a subject and the composition described herein is provided to the subject by an administrative route. The compositions described herein may be provided by a means of oral administration, parenteral administration, topical administration, ocular administration, intramuscular administration, transdermal administration, and/or nasal administration. Known means of said administrations are well known in the art.
The infection may be mild, moderate or severe. The infection may be a gastrointestinal infection, urogenital infection, respiratory infection, a skin infection, a systemic infection, a wound infection, and/or a sexually transmitted disease. The microorganism may reside in a subject and the composition described herein is provided to the subject by an administrative route. The compositions described herein may be provided by a means of oral administration, parenteral administration, topical administration, ocular administration, intramuscular administration, transdermal administration, and/or nasal administration. Known means of said administrations are well known in the art.
[0038] In even further embodiments are methods of treating an infection, such as a bacterial infection, or a parasitic infection, in a subject in need thereof. One representative method includes administering to a subject suspected of having the infection a therapeutically effective composition as described herein, in which the composition comprises a combination of agents comprising at least a fosfomycin, and one or more of a sulfonamide, and/or a diaminopyridine. The composition may also comprise a combination comprising at least a fosfomycin, a sulfonamide, and a diaminopyridine.
The therapeutically effective amount of the composition may increase the AUC
of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine upon administration as compared with an individual administration of any one of the fosfomycin, the sulfonamide, and the diaminopyridine when administered alone. The AUC may be the AUC/MIC or the f AUC/MIC (free drug AUC above the MIC), because the MIC is decreased for the combinations described herein.
Even when current doses of each of the components are used in combinations described herein (doses based on current indicated doses of each individual component when used individually), AUC in relation to the MIC is different in the combinations described herein. In some of the combinations described herein, AUC
in relation to MIC will drive efficacy of the novel combinations described herein. For example, AUC
in relation to MIC should drive efficacy of the fosfomycin component in the combinations described herein. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including an analog, or derivative thereof. The sulfonamide may be sulfamethoxazole, or one or more sulfonamides. The diaminopyridine may be one or more diaminopyridines. The diaminopyridine may be trimethoprim. The diaminopyridine may be pyrimethamine. The diaminopyridine may be trimethoprim and pyrimethamine, or similar or suitable combination. The infection may be selected from the group consisting of a gastrointestinal infection, urogenital infection, respiratory infection, a skin infection, a systemic infection, a wound infection, and a sexually transmitted disease. The infection may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The bacterial infection may be resistant to one or more antibacterial agents. The bacterial infection may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The bacterial infection may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The parasitic infection may be resistant to one or more antiparasitic agents. The sulfonamide to diaminopyridine, when both are included, may be in a ratio between about 3:1 and 6:1. The fosfomycin, the sulfonamide, and the diaminopyridine may be provided by administering in any one of the groups consisting of independently, sequentially, simultaneously, concomitantly, and combinations thereof. The subject may be any of a human, and an animal. The administering may be by any route selected from the group consisting of oral, parenteral, topical, ocular, intramuscular, transdermal, nasal, and combinations thereof.
The therapeutically effective amount of the composition may increase the AUC
of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine upon administration as compared with an individual administration of any one of the fosfomycin, the sulfonamide, and the diaminopyridine when administered alone. The AUC may be the AUC/MIC or the f AUC/MIC (free drug AUC above the MIC), because the MIC is decreased for the combinations described herein.
Even when current doses of each of the components are used in combinations described herein (doses based on current indicated doses of each individual component when used individually), AUC in relation to the MIC is different in the combinations described herein. In some of the combinations described herein, AUC
in relation to MIC will drive efficacy of the novel combinations described herein. For example, AUC
in relation to MIC should drive efficacy of the fosfomycin component in the combinations described herein. The fosfomycin may include a pharmaceutically acceptable salt, ester or prodrug, including an analog, or derivative thereof. The sulfonamide may be sulfamethoxazole, or one or more sulfonamides. The diaminopyridine may be one or more diaminopyridines. The diaminopyridine may be trimethoprim. The diaminopyridine may be pyrimethamine. The diaminopyridine may be trimethoprim and pyrimethamine, or similar or suitable combination. The infection may be selected from the group consisting of a gastrointestinal infection, urogenital infection, respiratory infection, a skin infection, a systemic infection, a wound infection, and a sexually transmitted disease. The infection may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The bacterial infection may be resistant to one or more antibacterial agents. The bacterial infection may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The bacterial infection may be resistant to one or more of the fosfomycin, the sulfonamide, and the diaminopyridine. The parasitic infection may be resistant to one or more antiparasitic agents. The sulfonamide to diaminopyridine, when both are included, may be in a ratio between about 3:1 and 6:1. The fosfomycin, the sulfonamide, and the diaminopyridine may be provided by administering in any one of the groups consisting of independently, sequentially, simultaneously, concomitantly, and combinations thereof. The subject may be any of a human, and an animal. The administering may be by any route selected from the group consisting of oral, parenteral, topical, ocular, intramuscular, transdermal, nasal, and combinations thereof.
[0039] With the description herein, novel antimicrobial compositions are provided, said compositions comprising at least a form of a fosfomycin or an analog, or derivative thereof, and a sulfonamide (or an analog, or derivative thereof), and/or a diaminopyridine (or an analog, or derivative thereof). Said antimicrobial compositions may and generally include two or more of said components. Some or all of said components may be provided as a combination, such as a single combination, or some or all of said components may be provided independently yet provided in a schedule or daily regimen for suitable, and/or maximal efficacy, and/or reduced dosing frequency, and/or reduced dosing amount. The dosing frequency and/or dosing amount of the two or more components will include a dosing of at least one of the components that is less than the dosing frequency and/or dosing amount when said one component is used alone. In one or more embodiments, the dosing frequency and/or dosing amount of the two or more components will include a dosing of each of the components in a dosing frequency and/or dosing amount that is considered safe, based at least in part on the safety of each of the two or more components when used alone. Said schedule, and the dosing frequency of the components, may be based on pharmacokinetic, and pharmacodynamic analysis. A representative example of such parameters is provided below.
[0040] The novel antimicrobial compositions described herein are found effective against susceptible microorganisms. The novel antimicrobial compositions when provided in an effective schedule and dosing frequency will be found effective against a broad spectrum of bacteria and/or parasites, which may include drug-resistant bacteria, multi-drug resistant bacteria, and/or drug-resistant parasites. Said drug-resistant bacteria and/or parasites may, in some embodiments, also be resistant to one, some, or all of the components of the novel antimicrobial composition described herein (e.g., one or more of the form of the fosfomycin, the sulfonamide, and/or the diaminopyridine, or when the sulfonamide, and the diaminopyridine, are provided as a combination).
[0041] In some embodiments, the antimicrobial pharmaceutical composition described herein comprises at least a therapeutically effective amount a fosfomycin; and a therapeutically effective amount at least one sulfonamide, such that the composition inhibits growth of a microorganism, or kills the microorganism, the microorganism suspected of causing an infection, such as a complicated bacterial infection, or a parasitic infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or prodrug, or an analog or derivative thereof, any of which have inhibitory activity in cell wall or peptidoglycan synthesis of the microorganism (e.g., acting on MurA), and the antimicrobial pharmaceutical composition being in a separable form, or a premix form. The sulfonamide may be provided as a pharmaceutically acceptable salt, ester, or prodrug, or an analog or derivative thereof.
The therapeutically effective amount of at least one of the fosfomycin, and the sulfonamide, may be less than an amount indicated as a therapeutically effective amount when used alone. The sulfonamide may be provided as sulfamethoxazole. The microorganism may be a microorganism resistant to the fosfomycin, and/or the sulfonamide.
The therapeutically effective amount of at least one of the fosfomycin, and the sulfonamide, may be less than an amount indicated as a therapeutically effective amount when used alone. The sulfonamide may be provided as sulfamethoxazole. The microorganism may be a microorganism resistant to the fosfomycin, and/or the sulfonamide.
[0042] In some embodiments, the antimicrobial pharmaceutical composition described herein comprise at least a therapeutically effective amount a fosfomycin; and a therapeutically effective amount at least one diaminopyridine, such that the composition inhibits growth of a microorganism, or kills the microorganism, the microorganism suspected of causing an infection, such as a complicated bacterial infection, or a parasitic infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester or prodrug, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the microorganism, and the antimicrobial pharmaceutical composition being in a separable form or a premix form. The therapeutically effective amount of at least one of the fosfomycin, and the diaminopyridine, may be less than an amount indicated as a therapeutically effective amount when used alone. The diaminopyridine may be provided as a pharmaceutically acceptable salt, ester, or prodrug, or an analog or derivative thereof. The diaminopyridine may be provided as trimethoprim. The diaminopyridine may be provided as pyrimethamine. The diaminopyridine may be provided as trimethoprim. The diaminopyridine may be provided as a combination of at least two diaminopyridines. The diaminopyridine may be provided as a combination of trimethoprim and pyrimethamine, as an example, providing activity as a broad spectrum antimicrobial agent, as an antibacterial agent and an antiparasitic agent.
[0043] In any of the described compositions, the composition may further comprise a carrier to increase the AUC of the composition or of at least one of the components of the composition. The carrier may increase said AUC upon administration, as compared with a composition without the carrier. In any of the described compositions, the composition may have an increased AUC/MIC
(because of lower MIC with the synergistic combination) upon administration, as compared with at least one of the fosfomycin, the sulfonamide, or the diaminopyridine, when said fosfomycin, sulfonamide, or diaminopyridine is used alone. In any of the compositions described herein, a therapeutically effective amount of the composition includes an amount of at least one of the components that is less than an amount of that component indicated as a therapeutically effective amount when used alone, such as for treatment of a bacterial infection for which one or more is indicated for use.
(because of lower MIC with the synergistic combination) upon administration, as compared with at least one of the fosfomycin, the sulfonamide, or the diaminopyridine, when said fosfomycin, sulfonamide, or diaminopyridine is used alone. In any of the compositions described herein, a therapeutically effective amount of the composition includes an amount of at least one of the components that is less than an amount of that component indicated as a therapeutically effective amount when used alone, such as for treatment of a bacterial infection for which one or more is indicated for use.
[0044] These and additional embodiments are further described below.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0045] For a more complete understanding of the description provided herein, and the advantages thereof, reference is now made to the brief description below, taken in connection with the accompanying drawing and detailed description.
[0046] FIG. 1 illustrates a representative, and known metabolic pathway;
[0047] FIG. 2 depicts a representative in vitro time-kill graph of the described composition on a known strain of E. coli as compared with alternative and individual antibiotic agents;
[0048] FIG. 3 depicts a representative in vitro time-kill graph of the described composition on a known nitrofurantoin-resistant strain of E. coli as compared with alternative and individual agents;
[0049] FIG. 4 depicts a representative in vitro time-kill graph of the described composition on a known strain of S. aureus as compared with alternative and individual antibiotic agents;
[0050] FIG. 5 depicts representative antibacterial mechanisms of activity when more than one agent is used in combination.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0051] Although making and using various embodiments are discussed in detail below, it should be appreciated that as described herein are provided many inventive concepts that may be embodied in a wide variety of contexts. Embodiments discussed herein are merely representative, and do not limit the scope of the invention.
[0052] The novel compositions described herein includes a combination of compounds or agents. Individually, each compound or agent on its own may provide only mild or moderate antimicrobial activity, and/or effectiveness. In combination, the grouping of said compounds or agents in the unique arrangements, and formulations described herein unexpectedly allow said compounds to behave synergistically. Surprisingly, the synergistic effect is greater than predicted.
[0053] The combination of the described composition includes at least a first compound or agent. The first compound or agent is or includes a form of a fosfomycin. In one or more forms, the fosfomycin has a structure as represented by formula I, or formula II, in which formula II is a fosfomycin salt depicted as a disodium salt, or formula III, which is a monobasic hydrosoluble fosfomycin salt depicted as fosfomycin tromethamine (fosfomycin-trometamol).
The fosfomycin includes any of said formulas, suitable analogues, derivatives, salts, esters, or prodrugs thereof. The salts may include, chemically, (-)(cis-1,2-epoxy-propyl)phosphonic acid. Said salts may include mono-salts, and di-salts (e.g., sodium, potassium, calcium, magnesium), as well as salts formed with amines, such as a-phenethylamine, quinine, lysine, procaine, etc., which can be mono- or di-salts.
The first compound or agent may also comprise any analogues, and derivatives, and salts thereof of the representative compounds as described, and illustrated but not limited to those of formula I, II, and III.
O
0,CH3 HO
The fosfomycin includes any of said formulas, suitable analogues, derivatives, salts, esters, or prodrugs thereof. The salts may include, chemically, (-)(cis-1,2-epoxy-propyl)phosphonic acid. Said salts may include mono-salts, and di-salts (e.g., sodium, potassium, calcium, magnesium), as well as salts formed with amines, such as a-phenethylamine, quinine, lysine, procaine, etc., which can be mono- or di-salts.
The first compound or agent may also comprise any analogues, and derivatives, and salts thereof of the representative compounds as described, and illustrated but not limited to those of formula I, II, and III.
O
0,CH3 HO
[0054] OH
O
H3C 7..p-ONa ONa
O
H3C 7..p-ONa ONa
[0055] 011.
[0056]
lì 0 OH
r 01-1 .H ¨CH2OH
A
H Q H CH,OH 111.
lì 0 OH
r 01-1 .H ¨CH2OH
A
H Q H CH,OH 111.
[0057] In some embodiments, a fosfomycin calcium salt form may be more suitable, such as when other salts are not suitable, or are too large. The first compound or agent may include analogues, and/or derivatives thereof having inhibitory activity of cell wall synthesis (inhibits MurA
or peptidoglycan synthesis).
or peptidoglycan synthesis).
[0058] The first compound or agent has activity against Gram-positive, and Gram-negative bacteria, and may be therapeutically useful in the treatment of infections caused thereby. These bacteria will include but are not limited to Staphylococcus aureus, Klebsiella sp., Streptococcus pyogenes, Enterobacter spp., Streptococcus pneumoniae, Serratia marcescens, Enterococcus faecalis, Pseudomonas aeruginosa, Neisseria meningitidis, Salmonella spp., Neisseria gonorrhoeae, Shigella spp., Haemophilus influenzae, Campylobacter jejuni, Legionella pneumophila, Yersinia enterocolitica, Escherichia coli, Acinetobacter calcoaceticus, Acinetobacter baumanii, Indole (-) Proteus spp., Vibrio cholerae, Indole (+) Proteus spp., Aeromonas spp., Peptococcus spp., Fusobacterium spp., Peptostreptococcus spp., Clostridium spp. The first compound or agent in some forms has a history of use, such as being provided orally, and by IV, for use with urinary tract infections, and respiratory tract infections, said use providing a long safety record, as is available to one of ordinary skill in this field.
[0059] A second compound of the described compositions may be or may include a sulfonamide or at least one sulfonamide having a functional group represented in formula IV.
[0060] R2 IV.
[0061] The sulfonamide may also include a N1 -heterocyclic substituted sulfonamide, such as a 5- or 6-membered heterocycle (e.g. a pyrimidine, pyrazine, pyridazine, oxazole, isoxazole, thiazole or thiadiazole ring). Specific examples include but are not limited to sulfadiazine, sulfamethoxazole, sulfatroxazole, sulfamerazine, sulfadoxine, sulfadimethoxine, sulfamethazine, sulfapyrazole, sulfaquinoxaline, sulfachloropyridazine, sulfaguanidine, sulfalene, sulfametin, sulfamethoxine, sulfamethoxy-pyridazine, sulfamethylphenazole, sulfaphenazole, sulfamoxole, sulfapyrazine, sulfapyridazine, sulfapyridine, sulfasymazine, sulfathiozole, sulfametrole, and sulfixoazole. The second compound may include analogues, derivatives, and/or prodrugs thereof having inhibitory activity in the synthesis of dihydrofolate, as depicted in FIG. 1 (see, e.g., top arrow "Second compound Block Here").
[0062] In one or more embodiments, the sulfonamide may be represented by sulfamethoxazole (SMX) represented by formula V, or may be its analogue, derivative, prodrug, salt, or thereof.
II 0 N'ID
II 0 N'ID
[0063] V.
[0064] The second compound or agent in the described compositions may also include or may further comprise or may be replaced by or at least one diaminopyridine, including those analogues, derivatives, and/or prodrugs that inhibit dihydrofolate reductase, as also depicted in FIG. 1 (bottom arrow "Second compound Blocks Here"). An example includes pyrimethamine.
Another example includes 2,4-diaminopyrimidine, and analogues, and derivatives thereof, such as 2,4-diamino-5-benzyl-pyrimidines. Further examples include but are not limited to 2,4-diamino-5-(4-amino-3,5-dichlorobenzyl)pyrimidine, 2,4-diamino-5-(3,5-dichloro-4-methylaminobenzyl)pyrimidine, 2,4-diamino-5-(3,5-dichloro-4-ethylaminobenzyl)pyrimidine, 2,4-diamino-5-(3,5-dichloro-4-dimethylaminobenzyl)pyrimidine, 4-diamino-5-(4-acetamido-3,5-dichlorobenzyl)pyrimidine. They may also include diaminopyridine with substitutions in the phenyl ring such as 2,4-diamino-5-(3,4,5-trimethoxybenzy1)-pyrimidine (trimethoprim), 2,4-diamino-5-[3,5-dimethoxy-4-(2-methoxyethoxy)benzy1]-pyrimidine (tetroxoprim), and 2,4-d iamino-5-(3,5-d imethoxy-4-methylthiobenzy1)-pyrimidine (metioprim). Other dihydrofolate reductase inhibitors include 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzy1)-pyrimidine, 2,4-d iamino-5-[3,5-d iethoxy-4-pyrrol-1-y1)-benzyI]-pyrimidine, 2,4-diamino-5-(3,4-dimethoxybenzyI)-pyrimidine (diaveridine),2,4-diamino-5-(p-chloropheny1)-6-ethylpyrimidine (pyrimethanine) 2,4-diamino-5-(2-methy1-4,5-dimethoxybenzy1)-pyrimidine; (RS)-5-[(2-cyclopropy1-7,8-d imethoxy-2H-ch romen-5-yl)methyl] pyrimid ine-2,4-d ia mine (iclaprim), and 5-[(4-bromo-3,5-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine (brodimoprim), as further non limiting examples.
Another example includes 2,4-diaminopyrimidine, and analogues, and derivatives thereof, such as 2,4-diamino-5-benzyl-pyrimidines. Further examples include but are not limited to 2,4-diamino-5-(4-amino-3,5-dichlorobenzyl)pyrimidine, 2,4-diamino-5-(3,5-dichloro-4-methylaminobenzyl)pyrimidine, 2,4-diamino-5-(3,5-dichloro-4-ethylaminobenzyl)pyrimidine, 2,4-diamino-5-(3,5-dichloro-4-dimethylaminobenzyl)pyrimidine, 4-diamino-5-(4-acetamido-3,5-dichlorobenzyl)pyrimidine. They may also include diaminopyridine with substitutions in the phenyl ring such as 2,4-diamino-5-(3,4,5-trimethoxybenzy1)-pyrimidine (trimethoprim), 2,4-diamino-5-[3,5-dimethoxy-4-(2-methoxyethoxy)benzy1]-pyrimidine (tetroxoprim), and 2,4-d iamino-5-(3,5-d imethoxy-4-methylthiobenzy1)-pyrimidine (metioprim). Other dihydrofolate reductase inhibitors include 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzy1)-pyrimidine, 2,4-d iamino-5-[3,5-d iethoxy-4-pyrrol-1-y1)-benzyI]-pyrimidine, 2,4-diamino-5-(3,4-dimethoxybenzyI)-pyrimidine (diaveridine),2,4-diamino-5-(p-chloropheny1)-6-ethylpyrimidine (pyrimethanine) 2,4-diamino-5-(2-methy1-4,5-dimethoxybenzy1)-pyrimidine; (RS)-5-[(2-cyclopropy1-7,8-d imethoxy-2H-ch romen-5-yl)methyl] pyrimid ine-2,4-d ia mine (iclaprim), and 5-[(4-bromo-3,5-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine (brodimoprim), as further non limiting examples.
[0065] In one or more embodiments, the diaminopyridine may be represented by a formula VI, which is pyrimethamine, or may be any analogue, derivative, prodrug, salt, or ester thereof.
H2N- '14 NH2
H2N- '14 NH2
[0066] VI.
[0067] In one or more embodiments, the diaminopyridine may be represented by a formula VII, which is trimethoprim (TMP), or may be any analogue, derivative, prodrug, salt, or ester thereof.
l a 1-,./3 N;...." I
l a 1-,./3 N;...." I
[0068] N VII.
[0069] The second compound may be one or more of a sulfonamide (SM), and/or a diaminopyridine (DP) having inhibitory activity in the dihydrofolate pathway (as described above).
[0070]
Interestingly, resistance to the first compound or agent, the fosfomycin (a phosphonic acid derivative, cis-1,2-epoxypropyl phosphonic acid, also provided as a monobasic hydrosoluble fosfomycin salt, or fosfomycin¨trometamol) has occurred, sometimes frequently, in many clinically relevant bacteria (both Gram negative, and Gram positive). As an anti-infective, it is only approved for use in the U.S. in a salt form as fosfomycin tromethamine ((1R,2S)-(1,2-epoxypropyl)phosphonic acid, and 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)) for treatment of mild (uncomplicated) urinary tract infection (acute cystitis) in women due to susceptible strains of Escherichia coli (Gram negative), and Enterococcus faecalis (Gram positive). The approved treatment is administration of a single oral dose, in which the active component is 3 g, given in the single dose. The minimum inhibitory concentration (MIC) of fosfomycin is 64 or less against said bacteria (i.e., 32-128 against E. faecalis, and 0.5-2 against E. coli). There is use of fosfomycin outside the U.S.
some more serious infections. In general, fosfomycin, and its salt forms are considered to have mild or moderate activity against Gram-positive, and/or Gram-negative microorganisms.
Interestingly, resistance to the first compound or agent, the fosfomycin (a phosphonic acid derivative, cis-1,2-epoxypropyl phosphonic acid, also provided as a monobasic hydrosoluble fosfomycin salt, or fosfomycin¨trometamol) has occurred, sometimes frequently, in many clinically relevant bacteria (both Gram negative, and Gram positive). As an anti-infective, it is only approved for use in the U.S. in a salt form as fosfomycin tromethamine ((1R,2S)-(1,2-epoxypropyl)phosphonic acid, and 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)) for treatment of mild (uncomplicated) urinary tract infection (acute cystitis) in women due to susceptible strains of Escherichia coli (Gram negative), and Enterococcus faecalis (Gram positive). The approved treatment is administration of a single oral dose, in which the active component is 3 g, given in the single dose. The minimum inhibitory concentration (MIC) of fosfomycin is 64 or less against said bacteria (i.e., 32-128 against E. faecalis, and 0.5-2 against E. coli). There is use of fosfomycin outside the U.S.
some more serious infections. In general, fosfomycin, and its salt forms are considered to have mild or moderate activity against Gram-positive, and/or Gram-negative microorganisms.
[0071] In some embodiments, a combination of a diaminopyridine (DP), such as a trimethoprim (2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or TMP) with a sulfonamide (SM), such as sulfamethoxazole (N1-(5-methyl-3-isoxazolyl)sulfanilamide or SMX) may form the second compound. A specific combination of trimethoprim (TMP), in combination with sulfamethoxazole (SMX) has been used in a combination approach, commonly referred to as TMP-SMX
or co-trimoxazole. The two agents (TMP and SMX) act along a same pathway, in which one inhibits synthesis of a compound one-step ahead of the other in a single metabolic path, which is the typical approach when using a combination of agents. This may also be referred to as sequential targeting depicted as pathway III in FIG. 5. In this pathway, SMX inhibits the synthesis of dihydrofolate from para-aminobenzoic acid, and TMP inhibits the next step or the production of tetrahydrofolate from dihydrofolate. Such sequential targeting for antimicrobial therapy has been attempted to overcome resistance of a single agent. Unfortunately, resistance has developed with sequential targeting approaches. This is often because sequential targeting, along with other approaches, identified as enhancing target access or pathway I in FIG. 5, and inhibiting resistance or pathway II in FIG. 5, have been applied empirically in the clinic with limited mechanistic rationale, or scientifically defined foundation. When a rationale is applied, it is often typically to combine two agents acting in tandem along a same metabolic pathway (one agent inhibiting synthesis of a compound one-step ahead of another in a single metabolic path), such as with co-trimoxazole.
or co-trimoxazole. The two agents (TMP and SMX) act along a same pathway, in which one inhibits synthesis of a compound one-step ahead of the other in a single metabolic path, which is the typical approach when using a combination of agents. This may also be referred to as sequential targeting depicted as pathway III in FIG. 5. In this pathway, SMX inhibits the synthesis of dihydrofolate from para-aminobenzoic acid, and TMP inhibits the next step or the production of tetrahydrofolate from dihydrofolate. Such sequential targeting for antimicrobial therapy has been attempted to overcome resistance of a single agent. Unfortunately, resistance has developed with sequential targeting approaches. This is often because sequential targeting, along with other approaches, identified as enhancing target access or pathway I in FIG. 5, and inhibiting resistance or pathway II in FIG. 5, have been applied empirically in the clinic with limited mechanistic rationale, or scientifically defined foundation. When a rationale is applied, it is often typically to combine two agents acting in tandem along a same metabolic pathway (one agent inhibiting synthesis of a compound one-step ahead of another in a single metabolic path), such as with co-trimoxazole.
[0072] While activity of co-trimoxazole can be considered synergistic, resistance to co-trimoxazole also occurs with some frequency in both Gram-positive, and Gram-negative microorganisms. Resistance is also common against TMP, which can be used alone. Co-trimoxazole was approved for use in the U.S. in 1973; TMP alone was approved for use in the U.S. in 1980.
[0073] Co-trimoxazole, like fosfomycin, is generally not considered for sustained activity against severe infections. As an anti-infective, co-trimoxazole is generally used against mild or moderate (uncomplicated) infections, including, for example, infections of the urinary tract (e.g., due to susceptible strains of at least the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris), for bronchitis (e.g., due to susceptible strains of Streptococcus pneumoniae, and Haemophilus influenzae), and otitis media (e.g., for acute infections due to susceptible strains of S.
pneumoniae or H. influenzae), skin (Staphylococcus aureus), with some prophylactic use against opportunistic infections (e.g., traveler's diarrhea due to susceptible strains of enterotoxigenic E. coli), and Pneumocystitis jiroveci.
TMP with SMX (co-trimoxazole) has a history of use, such as providing orally, and by IV, for use including with urinary tract infections; said use providing a long safety record. Administration of co-trimoxazole in the U.S. is usually once or twice a day (every 12 hours) for up to 14 or 21 days, in which a daily dose may include 80 or 160 mg of TMP, and 400 or 800 mg of SMX, respectively (for adults). The MIC of co-trimoxazole against organisms such as Enterobacter species, and H influenzae is also less than 64 lig/i.il (e.g., 2 lighil for TMP, and .38 lighil for SMX
against E. faecalis, and D3.5 lighil for TMP, and 9.5 lighil for SMX against H. influenzae).
pneumoniae or H. influenzae), skin (Staphylococcus aureus), with some prophylactic use against opportunistic infections (e.g., traveler's diarrhea due to susceptible strains of enterotoxigenic E. coli), and Pneumocystitis jiroveci.
TMP with SMX (co-trimoxazole) has a history of use, such as providing orally, and by IV, for use including with urinary tract infections; said use providing a long safety record. Administration of co-trimoxazole in the U.S. is usually once or twice a day (every 12 hours) for up to 14 or 21 days, in which a daily dose may include 80 or 160 mg of TMP, and 400 or 800 mg of SMX, respectively (for adults). The MIC of co-trimoxazole against organisms such as Enterobacter species, and H influenzae is also less than 64 lig/i.il (e.g., 2 lighil for TMP, and .38 lighil for SMX
against E. faecalis, and D3.5 lighil for TMP, and 9.5 lighil for SMX against H. influenzae).
[0074]
Fosfomycin is considered bactericidal (bacterial killing). SMX alone, and TMP
alone are each considered bacteriostatic (bacteria inhibiting, by inhibiting metabolism of folic acid).
Fosfomycin is considered bactericidal (bacterial killing). SMX alone, and TMP
alone are each considered bacteriostatic (bacteria inhibiting, by inhibiting metabolism of folic acid).
[0075]
Unexpectedly, the combination described herein of the first compound or agent (a form of fosfomycin, its analogue, derivative, prodrug, etc., which may also be referred to herein as fosfomycin) with the second compound (comprising one or both DP, and/or SM or as a form of co-trimoxazole) has a very robust, and unexpected synergistic effect, greater than the activity of each, which is either the form of fosfomycin when used alone or is, for example, DP, and/or SM when used. The synergistic effect contradicts some literature suggesting that rapidly bactericidal agents, such as fosfomycin, producing by-products, and/or toxins that appear directly related to morbidity, may be antagonized by bacteriostatic agents. The magnitude of synergism as has been found with the described combination of a first bactericidal antimicrobial or antibiotic agent (some form of fosfomycin, its analogue, derivative, prodrug, etc.), and a second antimicrobial or antibiotic agent (one or both DP, and/or SM or as a form of co-trimoxazole) was not predicted.
Unexpectedly, the combination described herein of the first compound or agent (a form of fosfomycin, its analogue, derivative, prodrug, etc., which may also be referred to herein as fosfomycin) with the second compound (comprising one or both DP, and/or SM or as a form of co-trimoxazole) has a very robust, and unexpected synergistic effect, greater than the activity of each, which is either the form of fosfomycin when used alone or is, for example, DP, and/or SM when used. The synergistic effect contradicts some literature suggesting that rapidly bactericidal agents, such as fosfomycin, producing by-products, and/or toxins that appear directly related to morbidity, may be antagonized by bacteriostatic agents. The magnitude of synergism as has been found with the described combination of a first bactericidal antimicrobial or antibiotic agent (some form of fosfomycin, its analogue, derivative, prodrug, etc.), and a second antimicrobial or antibiotic agent (one or both DP, and/or SM or as a form of co-trimoxazole) was not predicted.
[0076] The metabolic pathway affected by DP, and SM, which reversibly inhibits successive steps in folate metabolism, as depicted in FIG. 1, is not directly affected by fosfomycin. Instead, fosfomycin acts on a separate, and distinct path, blocking irreversibly peptidoglycan biosynthesis by inhibiting UDP-GIcNAc enolpyruvyl transferase (MurA). Without being bound by theory it is proposed herein that the fosfomycin pathway (in which fosfomycin has activity) is somewhat convergent with that of folate synthesis. Without being bound by theory, substrate metabolites from both pathways appear to be or are subsequently utilized as reactants in a single enzymatically-mediated chemical reaction or process. As such, a metabolite is the reactant for an enzymatic-mediated process in a second pathway, and a first antimicrobial or antibiotic that targeted the necessary pathway to produce the reactant has been combined with a second antimicrobial or antibiotic that was a specific enzyme inhibitor of the distinct reaction in the second pathway.
[0077] The above, however, does not explain additional unexpected findings in which the combination described herein, containing the fosfomycin, the sulfonamide, and/or the diaminopyridine, has also been found to have superior activity against drug resistant bacteria, including bacterial strains resistant to one or both fosfomycin, and co-trimoxazole or its components individually. In view of the findings described herein, it is believed that in a resistant organism only partial inhibition of biochemical synthesis occurs with introduction of a first inhibitor (such as the first compound or agent described herein) even though bacterial growth is not inhibited. When a second inhibitor (such as the second compound described herein), having convergent inhibitory effect, is introduced, there is concomitant partial inhibition of bacterial growth that, together, disrupts at least one essential metabolite synthesis. This is generally depicted in pathway IV or FIG.
5, in which a first component having a first target (e.g., Effect C in FIG. 5) and a second component having at least one second target (Effect B in FIG. 5) together provide an enhanced overall outcome (Outcome S in FIG. 5), which is synergistic. Thus, the composition, and combination as described herein is unique, and was found to deliver novel, and surprising effects which superseded any predicted synergistic effect. It is expected and is shown below that the spontaneous mutational frequency of bacteria (either Gram positive or Gram negative) when in the presence of the described composition (containing the fosfomycin, DP, and/or SM) is markedly lower than what is found when said agents are used alone (e.g., fosfomycin alone, co-trimoxazole alone, or TMP alone). The lower incidence of two concomitant distinct mutations¨one affecting each pathway, as occurs with the unique compositions described herein¨further reduce the incidence or development of new resistance. In fact, as described herein, the synergy (Outcome S, in FIG. 5) found with the described combination of the first compound or agent, and the second compound or agent not only greatly improved bacterial potency, the compositions as described herein overcame resistance, and increased the spectrum of activity, as compared with the resistance profiles, and the spectrum of activity found with independent use of the first compound or agent or the second compound or agent. The synergy was measured by known techniques, including checkerboard assay, killing curve (time-kill curve), disk diffusion, and/or kinetic spectrophotometry.
5, in which a first component having a first target (e.g., Effect C in FIG. 5) and a second component having at least one second target (Effect B in FIG. 5) together provide an enhanced overall outcome (Outcome S in FIG. 5), which is synergistic. Thus, the composition, and combination as described herein is unique, and was found to deliver novel, and surprising effects which superseded any predicted synergistic effect. It is expected and is shown below that the spontaneous mutational frequency of bacteria (either Gram positive or Gram negative) when in the presence of the described composition (containing the fosfomycin, DP, and/or SM) is markedly lower than what is found when said agents are used alone (e.g., fosfomycin alone, co-trimoxazole alone, or TMP alone). The lower incidence of two concomitant distinct mutations¨one affecting each pathway, as occurs with the unique compositions described herein¨further reduce the incidence or development of new resistance. In fact, as described herein, the synergy (Outcome S, in FIG. 5) found with the described combination of the first compound or agent, and the second compound or agent not only greatly improved bacterial potency, the compositions as described herein overcame resistance, and increased the spectrum of activity, as compared with the resistance profiles, and the spectrum of activity found with independent use of the first compound or agent or the second compound or agent. The synergy was measured by known techniques, including checkerboard assay, killing curve (time-kill curve), disk diffusion, and/or kinetic spectrophotometry.
[0078] As used herein, the described composition, containing the fosfomycin, with the sulfonamide, and/or the diaminopyridine, may also include any comparable analogue, derivative or synthetic (such as so-called equivalents) of any one or more of the fosfomycin, the sulfonamide, and/or the diaminopyridine. The compositions in any of the combinations described herein may also comprise a co-administration of any one or more of the described first, and/or described second compounds or agents. The co-administration may be provided sequentially or concomitantly. The co-administration may also comprise a pre-mix of the some or all of the components as described herein. The composition may comprise a co-formulation of any one or more of the described first, and/or second compounds or agents.
[0079] In use, the described composition, containing at least two of the fosfomycin, the sulfonamide, and the diaminopyridine will, in some embodiments, be provided at dosages that differ from their independent use. For example, in the U.S., independently fosfomycin on its own is generally delivered once, in a dose that is generally 3 g (i.e., for uncomplicated urinary tract infections). At this dose, fosfomycin is only weakly bactericidal. Co-trimoxazole on its own is generally delivered twice daily, and up to four times daily, in a ratio of TMP
to SMX that is 1:5, a dosing regimen that often includes a duration of at least about seven days and a maximum of about 21 days. At these current regimens, co-trimoxazole also behaves like a weak bactericidal agent. On the other hand, with the combinations described herein, the combination is strongly bactericidal, with better MIC (lower MIC for all components). With the combinations described herein, the dosing amount, and/or schedule of dosing have changed due to the synergistic effect, and significantly lower MICs when provided as the described combination. For example, at least one of the compounds when provided in the unique combination described herein (fosfomycin plus one or more of the sulfonamide, and/or the diaminopyridine) will include a lower amount of either or both the first compound (fosfomycin), and/or the second compound (sulfonamide, and/or diaminopyridine). Any of said combinations as described herein should be effective in inhibiting growth and or treating an infection caused by one or more susceptible microorganisms, including serious infections, due to an ability of the combinations described herein to achieve adequate concentrations at a site of infection. The combination as described herein should remain above the MIC of the susceptible microorganism (e.g., at the site of infection) beyond a time necessary to achieve optimal pharmacodynamic effect.
to SMX that is 1:5, a dosing regimen that often includes a duration of at least about seven days and a maximum of about 21 days. At these current regimens, co-trimoxazole also behaves like a weak bactericidal agent. On the other hand, with the combinations described herein, the combination is strongly bactericidal, with better MIC (lower MIC for all components). With the combinations described herein, the dosing amount, and/or schedule of dosing have changed due to the synergistic effect, and significantly lower MICs when provided as the described combination. For example, at least one of the compounds when provided in the unique combination described herein (fosfomycin plus one or more of the sulfonamide, and/or the diaminopyridine) will include a lower amount of either or both the first compound (fosfomycin), and/or the second compound (sulfonamide, and/or diaminopyridine). Any of said combinations as described herein should be effective in inhibiting growth and or treating an infection caused by one or more susceptible microorganisms, including serious infections, due to an ability of the combinations described herein to achieve adequate concentrations at a site of infection. The combination as described herein should remain above the MIC of the susceptible microorganism (e.g., at the site of infection) beyond a time necessary to achieve optimal pharmacodynamic effect.
[0080] A dosing regimen of the described novel combination may include, for example, a once daily, twice daily, or up to six times per day of the described composition, in which fosfomycin is in an amount from between about 1-8 g per dose, and DP and/or SM (or as co-trimoxazole) is in an amount of between about 40 mg to 800 mg per dose. Because the combination of agents described herein has been found to have such high activity (often far greater than the compounds when used individually), the actual doses of each agent when administered to a subject in need does not need to be increased from, which avoids toxicity, and reduces adverse events. In some embodiments, the actual does of each agent when administered to a subject in need will be less than current dosing of said agents when use alone. For example, there may be a once daily, twice daily, or up to six times per day of the described composition, in which fosfomycin is in an amount from between about 1-8 g per dose, and DP and/or SM (or as co-trimoxazole) is in an amount of between about 40 mg to 800 mg per dose.
[0081] In some embodiments, a dosing regimen of the described novel combination may include one or more doses of the first compound or agent, and/or the second compound or agent currently used clinically. Said doses can also be optimized by pharmacodynamics, and pharmacokinetic data, thereby achieving a better clinical outcome in vivo as compared with outcome of said first compound or agent or second compound or agent when used independently.
Said doses may be optimized to increase the AUC of the novel combination or provide an improved AUC for the novel combination, such as upon administration (oral, IV, inhalation, as examples), as compared to a same mode of administration with one of the components used individually. Said doses may be optimized to increase the AUC of the novel combination or provide an improved AUC
for the novel combination, upon administration (oral, inhalation, or IV as examples), with inclusion of an effective amount of a carrier, as compared to administration using a same mode with one of the components individually, or as compared with administration using the same mode for the novel combination without said carrier. The carrier may include one or more of an effective linear chain polysaccharide, such as a cellulose, or microcrystalline cellulose, or hydroxymethyl cellulose, or hydroxypropylcellulose, or a polyvinylpyrrolidone, the carrier included in an amount that is at or less than 50% of the novel composition, or at or less than 40% of the novel composition, or at or less than 30% of the novel composition. The carrier may interact (physically, chemically, and/or transiently) with one or more of the components (first compound, and/or second compound) of the novel compositions described herein. Said dosing regimen when including current clinically useful doses for one or both of the first compound or agent, and second compounds or agent may, in many embodiments, result in an improved outcome (therapeutically, and/or clinically) as compared with outcome when only the first compound or agent or only the second compound or agent are provided independently at said (same) clinically useful dose. Further, in some embodiments, said dosing regimen when including current clinically useful doses for one or both of the independent first, and second compounds or agents may be provided to a subject having resistance or exhibiting clinical resistance to one or both of the first compound or agent, and the second compound or agent, thereby providing an improved outcome (therapeutically, and/or clinically) as compared with the outcome when only the first compound or agent or only the second compound or agent were provided independently at said (same) current clinically useful dose.
Said doses may be optimized to increase the AUC of the novel combination or provide an improved AUC for the novel combination, such as upon administration (oral, IV, inhalation, as examples), as compared to a same mode of administration with one of the components used individually. Said doses may be optimized to increase the AUC of the novel combination or provide an improved AUC
for the novel combination, upon administration (oral, inhalation, or IV as examples), with inclusion of an effective amount of a carrier, as compared to administration using a same mode with one of the components individually, or as compared with administration using the same mode for the novel combination without said carrier. The carrier may include one or more of an effective linear chain polysaccharide, such as a cellulose, or microcrystalline cellulose, or hydroxymethyl cellulose, or hydroxypropylcellulose, or a polyvinylpyrrolidone, the carrier included in an amount that is at or less than 50% of the novel composition, or at or less than 40% of the novel composition, or at or less than 30% of the novel composition. The carrier may interact (physically, chemically, and/or transiently) with one or more of the components (first compound, and/or second compound) of the novel compositions described herein. Said dosing regimen when including current clinically useful doses for one or both of the first compound or agent, and second compounds or agent may, in many embodiments, result in an improved outcome (therapeutically, and/or clinically) as compared with outcome when only the first compound or agent or only the second compound or agent are provided independently at said (same) clinically useful dose. Further, in some embodiments, said dosing regimen when including current clinically useful doses for one or both of the independent first, and second compounds or agents may be provided to a subject having resistance or exhibiting clinical resistance to one or both of the first compound or agent, and the second compound or agent, thereby providing an improved outcome (therapeutically, and/or clinically) as compared with the outcome when only the first compound or agent or only the second compound or agent were provided independently at said (same) current clinically useful dose.
[0082]
Evaluations of the described novel combination were performed in vitro against S.
aureus, E. coli, K. pneumoniae, and P. aeruginosa strains, as provided in the tables below.
Evaluations of the described novel combination were performed in vitro against S.
aureus, E. coli, K. pneumoniae, and P. aeruginosa strains, as provided in the tables below.
[0083] The described novel combination was tested against both reference, and clinically resistant strains of S. aureus, E, coli, K. pneumoniae, and P. aeruginosa.
Reference and clinical isolates were obtained from the American Type Culture Collection (ATCC, Manasas, VA.) and International Health Management Associates, Inc. (Schaumberg, IL). Bacteria were cultured in trypticase soy broth, concentrated 10-fold by centrifugation, and cryopreserved in the same medium containing 20% glycerol by holding at -80 C. Every two weeks a small amount of frozen culture was removed aseptically, and streaked on fresh trypticase soy agar plates to act as a working inoculum.
Following overnight growth at about 37 C, the plates were wrapped in parafilm, and held at about 4 C. Bacteria (4-5 colonies) were then aseptically transferred into broth growth medium for assays as needed.
Reference and clinical isolates were obtained from the American Type Culture Collection (ATCC, Manasas, VA.) and International Health Management Associates, Inc. (Schaumberg, IL). Bacteria were cultured in trypticase soy broth, concentrated 10-fold by centrifugation, and cryopreserved in the same medium containing 20% glycerol by holding at -80 C. Every two weeks a small amount of frozen culture was removed aseptically, and streaked on fresh trypticase soy agar plates to act as a working inoculum.
Following overnight growth at about 37 C, the plates were wrapped in parafilm, and held at about 4 C. Bacteria (4-5 colonies) were then aseptically transferred into broth growth medium for assays as needed.
[0084] Minimal inhibitory concentration (MIC) assays were performed in a manner as described for the CLSI Agar dilution or broth microdilution assay guideline (see, Clinical Laboratory Standards Institute, 2009, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, Eighth Edition, M07-A8, Vol. 29, No. 2). For example, known antibiotics or the compositions described herein were dissolved, serially diluted, and then added to tempered molten Mueller-Hinton Agar before pouring of plates; or were dissolved, and then serially diluted in 100 11.1_ cation-adjusted Mueller-Hinton broth across the assay plate in the classical 2-fold geometric format. D-glucose-6-phosphate was included as a medium supplement in both agar, and broth at a concentration of 50 mg/L. Antibiotic concentrations for agar assay were at the final concentration. Antibiotic concentrations for broth microdilution in each well at this point were double what the final assay concentration would be. Bacterial inocula were prepared by swabbing several colonies from a fresh agar plate, and resuspending the bacteria to a density that was the 0.5 McFarland turbidity standard, considered close or equivalent to 1x108CFU/mL.
For agar dilution, a steers replicator was utilized to deliver 1 x 104 CFU/spot. For broth microdilution, the bacterial inocula were diluted in the cation-adjusted Mueller-Hinton broth to 1x106CFU/mL, and 100 11.1_ was overlayered onto the wells containing a diluted antibiotic or a composition described. Following incubation as per the guideline, results were recorded as growth or no growth, and the lowest concentration of the antibiotic or the composition described where no growth was observed was declared the MIC.
For agar dilution, a steers replicator was utilized to deliver 1 x 104 CFU/spot. For broth microdilution, the bacterial inocula were diluted in the cation-adjusted Mueller-Hinton broth to 1x106CFU/mL, and 100 11.1_ was overlayered onto the wells containing a diluted antibiotic or a composition described. Following incubation as per the guideline, results were recorded as growth or no growth, and the lowest concentration of the antibiotic or the composition described where no growth was observed was declared the MIC.
[0085] To assay for synergy of antibacterial combinations, a recognized synergy checkerboard assay, adapted from the CLSI guideline microdilution assay, was utilized (see Eliopoulos, G.M., and Moellering, R.C, Jr., 1996. Antimicrobial Combinations, pg. 330-396. In:
Lorian, V. (Ed.), Antibiotics in Laboratory Medicine, 4th Ed., Williams & Wilkins; Baltimore, MD). In the case of the agar dilution method, each antibiotic alone, or in combination was added to agar prior to plate pouring. For broth microdilution, the first compound (or antibiotic or agent) was diluted in cation-adjusted Mueller-Hinton broth across the plate along the horizontal axis with each well in a row containing 504 of an identical concentration of compound (or antibiotic). Along the vertical axis a dilution series of the second compound (or antibiotic) was dispensed. At this point the drug concentrations are four fold of the final desired working concentration. The bacterial inoculum is prepared as described above for the MIC assay, and 100 11.1_ of culture is overlayered onto the combined compound (or antibiotic) matrix. Following incubation, wells with no growth are noted. The fractional inhibitory concentration, which provides the mathematical definition (as shown below) is calculated to determine whether there was synergy, or the MIC concentrations for fosfomycin, and trimethoprim for the combination were utilized for the calculation because the MIC for trimethoprim is commonly utilized to represent the value, and susceptibility of bacteria isolates to co-trimoxazole.
Lorian, V. (Ed.), Antibiotics in Laboratory Medicine, 4th Ed., Williams & Wilkins; Baltimore, MD). In the case of the agar dilution method, each antibiotic alone, or in combination was added to agar prior to plate pouring. For broth microdilution, the first compound (or antibiotic or agent) was diluted in cation-adjusted Mueller-Hinton broth across the plate along the horizontal axis with each well in a row containing 504 of an identical concentration of compound (or antibiotic). Along the vertical axis a dilution series of the second compound (or antibiotic) was dispensed. At this point the drug concentrations are four fold of the final desired working concentration. The bacterial inoculum is prepared as described above for the MIC assay, and 100 11.1_ of culture is overlayered onto the combined compound (or antibiotic) matrix. Following incubation, wells with no growth are noted. The fractional inhibitory concentration, which provides the mathematical definition (as shown below) is calculated to determine whether there was synergy, or the MIC concentrations for fosfomycin, and trimethoprim for the combination were utilized for the calculation because the MIC for trimethoprim is commonly utilized to represent the value, and susceptibility of bacteria isolates to co-trimoxazole.
[0086] FIC = (MIC-A combination / MIC-A alone) + (MIC-B combination/MIC-B
alone).
alone).
[0087] In the above, FIC: Synergy = FIC <0.5; Additive = FIC >0.5-1;
Indifferent = FIC >1-2;
Antagonism = FIC >2-4.
Indifferent = FIC >1-2;
Antagonism = FIC >2-4.
[0088] Synergy was also assayed by both agar, and broth microdilution methods. Additional information gathered about the synergistic effect of the described composition as a combination therapy was evaluated by determining bacterial killing effect. This was performed as described above for the checkerboard synergy assay with the exception that the bacterial count in an assay well was determined by plating at the beginning of the experiment, and identifying at the end of incubation for an assay well where growth was inhibited. This has been adapted from both the broth microdilution, and the bactericidal assays (Clinical Laboratory Standards Institute (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents;
Approved Guideline M26-A, Vol. 19, No. 18). One additional difference from the guideline assay was that the starting inoculums were 5 x 105 CFU/mL as per the MIC assay instead of 1 x 106 CFU/mL in the guideline minimal bactericidal concentration assay. The value derived was the reduction in bacterial numbers (viability) for the compounds when alone versus the described composition comprising the combined antibiotics.
Approved Guideline M26-A, Vol. 19, No. 18). One additional difference from the guideline assay was that the starting inoculums were 5 x 105 CFU/mL as per the MIC assay instead of 1 x 106 CFU/mL in the guideline minimal bactericidal concentration assay. The value derived was the reduction in bacterial numbers (viability) for the compounds when alone versus the described composition comprising the combined antibiotics.
[0089]
Synergism was found using the checkerboard microdilution assay, in which synergy was considered as a four-fold reduction in MIC. In fact, the synergistic effect of the described composition on all isolates was as much as an 8-fold reduction or as much as a 16-fold reduction.
FIC values were <0.5.
Synergism was found using the checkerboard microdilution assay, in which synergy was considered as a four-fold reduction in MIC. In fact, the synergistic effect of the described composition on all isolates was as much as an 8-fold reduction or as much as a 16-fold reduction.
FIC values were <0.5.
[0090]
Bactericidal synergy was demonstrated by determining the minimal bactericidal concentration, >3 log10 reduction was observed for the combination ranging from 2-fold to as much as 266-fold reduction in concentrations of the individual agents.
Bactericidal synergy was demonstrated by determining the minimal bactericidal concentration, >3 log10 reduction was observed for the combination ranging from 2-fold to as much as 266-fold reduction in concentrations of the individual agents.
[0091] Similarly, bactericidal synergy was greater than the defined value of log10 change in viable count assessed by a time-kill assay after 24 hours.
[0092] The time kill assay was performed sequentially to the checkerboard synergy studies.
Fifty milliliter Erlenmeyer flasks containing 10 mL of pre-warmed sterile cation-adjusted Mueller-Hinton Broth with or without antibiotic or the composition described herein were inoculated with bacteria to a starting level of 1 x 106 CFU/mL, followed by incubation at 37 C with shaking (-200 rpm). At various time points, aliquots were withdrawn, serially diluted in antibiotic-free broth medium, and 0.1 mL aliquots of each dilution were spread plated on Trypticase soy agar plates.
Enumeration was by counting colonies after 24-hours further incubation of the plates at 37 C, and calculating the reduction in viable bacteria.
Fifty milliliter Erlenmeyer flasks containing 10 mL of pre-warmed sterile cation-adjusted Mueller-Hinton Broth with or without antibiotic or the composition described herein were inoculated with bacteria to a starting level of 1 x 106 CFU/mL, followed by incubation at 37 C with shaking (-200 rpm). At various time points, aliquots were withdrawn, serially diluted in antibiotic-free broth medium, and 0.1 mL aliquots of each dilution were spread plated on Trypticase soy agar plates.
Enumeration was by counting colonies after 24-hours further incubation of the plates at 37 C, and calculating the reduction in viable bacteria.
[0093] The unique reduction in spontaneous mutational frequency, an indicator of the potential to experience lessened pre-existing antibiotic resistance from a bacterial population, was evaluated for the composition combination described herein, as well as for the fosfomycin and co-trimoxazole individually. To perform this study, a bacterial inoculum was prepared as described above for the minimal inhibitory concentration assay, and viable bacteria level confirmed by plate count, and 0.1 mL aliquots (1 x 109 CFU/mL) of the bacteria were spread plated onto up to 500 Trypticase soy agar plates containing 4-fold MIC of the combination or 2-fold MIC or each antibiotic (fosfomycin or co-trimoxazole) alone providing a cumulative bacterial population of approximately 1 x 1010 in order to afford detection of a low resistance frequency. Following 24-hour incubation at 37 C, any colonies that grew up as suspect resistant mutants were streaked onto fresh agar plates of the same composition combination or antibiotic containing media to confirm resistance.
MIC was further evaluated to confirm resistance, and the spontaneous mutational frequency was calculated based on the following equation:
MIC was further evaluated to confirm resistance, and the spontaneous mutational frequency was calculated based on the following equation:
[0094] (Numbers of viable resistant bacterial cells) (Total numbers of viable bacterial cells inoculated) (1).
[0095] The MIC
(in g/ml), and the fractional inhibitory concentration (FIC) of novel combination described herein against a wide variety of microorganisms, including Gram positive, and Gram negative bacteria presenting as clinically resistant, are provided in TABLE 1, demonstrating synergy, using a broth checkerboard assay, in which the novel composition described herein (Combo) was compared with each of the first compound or agent (as fosfomycin), and the second compound (as DP, and SM) when used alone. In TABLE 1, the second compound was a known DP
and SM combination of trimethoprim and sulfamethoxazole or co-trimoxazole (in which data represents their independent MICs), and the Combo was the fosfomycin with the DP, and SM of the second compound. For FIC, synergy (S) was 0.5; additive (A) was > 0.5-1;
indifferent (I) was >1-2;
and antagonistic (X) was >2. Bacterial strains resistant to antibiotics (*) as noted were based on reported CLSI susceptibility breakpoints: Fosfomycin, 64 p.g/ml, S; co-trimoxazole, 2/38 p.g/ml, S.
Combo (1.1g/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound) Bacteria (1.1g/m1) (1.1g/m1) (1.1g/m1) Staphylococcus aureus 0.25/0.125/2.38 32 0.5/9.5 0.26 (ATCC 29213 - MSSA) Staphylococcus aureus 8/0.25/4.75 64 2/38 0.25 (ATCC 33591) Staphylococcus aureus 32/1/19 128* 4/76* 0.5 (MGH-04) Staphylococcus aureus (918019MRSA) 4/0.125/2.38 32 0.5/9.5 0.38 -Staphylococcus aureus (959797 - MRSA) 2/0.25/4.75 16 2/38 0.25 Staphylococcus aureus 16/0.125/2.38 64 0.5/9.5 0.5 (USA-300 CDC - MRSA) Enterococcus faecalis 64/2/38 256* >8/152* <0.38 (MGH-01) (VanA) Enterococcus faecalis 32/0.5/9.5 128* 4/76* 0.38 (MGH-06) Enterococcus faecalis 16/0.25/4.75 64 1/19 0.5 (ATCC 29212) Escherichia coli 0.03/0.125/2.38 8 0.5/9.5 0.25 (ATCC 25922) Escherichia coli 16/2/38 64 8/152* 0.5 (854535) Escherichia coli 16/0.03/0.6 64 0.25/4.75 0.38 (928017) Pseudomonas aeruginosa 32/2/38 256* 4/76* 0.63 (924190) Pseudomonas aeruginosa 32/0.5/9.5 128* 2/38 0.5 (985543)
(in g/ml), and the fractional inhibitory concentration (FIC) of novel combination described herein against a wide variety of microorganisms, including Gram positive, and Gram negative bacteria presenting as clinically resistant, are provided in TABLE 1, demonstrating synergy, using a broth checkerboard assay, in which the novel composition described herein (Combo) was compared with each of the first compound or agent (as fosfomycin), and the second compound (as DP, and SM) when used alone. In TABLE 1, the second compound was a known DP
and SM combination of trimethoprim and sulfamethoxazole or co-trimoxazole (in which data represents their independent MICs), and the Combo was the fosfomycin with the DP, and SM of the second compound. For FIC, synergy (S) was 0.5; additive (A) was > 0.5-1;
indifferent (I) was >1-2;
and antagonistic (X) was >2. Bacterial strains resistant to antibiotics (*) as noted were based on reported CLSI susceptibility breakpoints: Fosfomycin, 64 p.g/ml, S; co-trimoxazole, 2/38 p.g/ml, S.
Combo (1.1g/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound) Bacteria (1.1g/m1) (1.1g/m1) (1.1g/m1) Staphylococcus aureus 0.25/0.125/2.38 32 0.5/9.5 0.26 (ATCC 29213 - MSSA) Staphylococcus aureus 8/0.25/4.75 64 2/38 0.25 (ATCC 33591) Staphylococcus aureus 32/1/19 128* 4/76* 0.5 (MGH-04) Staphylococcus aureus (918019MRSA) 4/0.125/2.38 32 0.5/9.5 0.38 -Staphylococcus aureus (959797 - MRSA) 2/0.25/4.75 16 2/38 0.25 Staphylococcus aureus 16/0.125/2.38 64 0.5/9.5 0.5 (USA-300 CDC - MRSA) Enterococcus faecalis 64/2/38 256* >8/152* <0.38 (MGH-01) (VanA) Enterococcus faecalis 32/0.5/9.5 128* 4/76* 0.38 (MGH-06) Enterococcus faecalis 16/0.25/4.75 64 1/19 0.5 (ATCC 29212) Escherichia coli 0.03/0.125/2.38 8 0.5/9.5 0.25 (ATCC 25922) Escherichia coli 16/2/38 64 8/152* 0.5 (854535) Escherichia coli 16/0.03/0.6 64 0.25/4.75 0.38 (928017) Pseudomonas aeruginosa 32/2/38 256* 4/76* 0.63 (924190) Pseudomonas aeruginosa 32/0.5/9.5 128* 2/38 0.5 (985543)
[0096] In view of TABLE 1, clinically relevant broad spectrum synergy was demonstrated for a composition comprising the first compound and the second compound, in which the described composition was effective against bacterial strains, including strains resistant to one or both of the trimethoprim, and the sulfamethoxazole. Additional synergy is identified in TABLE 2 (utilizing the broth checkerboard assay) and TABLE 3 (utilizing the agar checkerboard assay) for E. coli; TABLE 4 (utilizing the broth checkerboard assay) and TABLE 5 (utilizing the agar checkerboard assay) for K.
pneumonia; TABLE 6 (utilizing the broth checkerboard assay) and TABLE 7 (utilizing the agar checkerboard assay) for P. aeruginosa. In these analyses. For FIC, synergy (S) was 0.5; additive (A) was 13.5-1;
indifferent (I) was >1-2; antagonistic (X) was >2); and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S. MIC comparator data was performed using the following known antibiotics: Amoxicillin/clavulanic acid, Cefotoxitin, Cefotaxime, Ceftazidime, Ceftriaxone, Piperacillin, Ampicillin, Merropenem, Polymixin B, Tobramycin, Amikacin, Ciprofloxacin (data not shown). The strains of E. coli in the comparator analyses included extended spectrum beta-lactamase (ESBL) producers based on phenotype (e.g., Amoxicillin/clavulanic acid resistance, or Cefotoxitin resistance), as well as carbapenem resistant, or quinolone resistant (15 strains). Strains of K. pneumonia in the comparator analyses were highly resistant to many of the clinical comparators, a number of these strains express ESBLs based on phenotype, and several were carbapenem, and quinolone resistant. Strains of K. pneumonia in the comparator analyses were highly resistant to commonly utilized clinical comparators, including 3rd-generation cephalosporins, carbapenems, aminoglycosides, and quinolones.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy Escherichia coli (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
846439 8/0.25/4.75 32 >4/76* D3.28 S
846446 0.25/0.06/1.25 2 >4/76* <0.13 S
846450 4/2/38 16 >4/76* <0.5 S
857021 8/2/38 32 >4/76* <0.5 S
863686 8/2/38 32 >4/76* <0.5 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy Escherichia coli (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
846439 16/0.5/9.5 64 8/152* 0.31 S
846446 1/0.125/2.38 4 8/152* 0.26 S
846450 8/2/38 32 8/152* 0.5 S
846455 4/1/19 128* 4/76* 0.28 S
847149 16/1/19 128* 4/76* 0.38 S
854535 64/1/19 128* 4/76* 0.75 A
854566 4/1/19 128* 4/76* 0.28 S
857021 16/2/38 64 8/152* 0.5 S
863078 4/1/19 128* 4/76* 0.28 S
863686 16/2/38 64 16/304* 0.38 S
ATCC 25922 0.12/0.25/4.75 16 1/19 0.26 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy K. pneumoniae (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
848788 ND >64* >4/76* ND ND
857147 4/0.06/1.19 16 >4/76* D3.26 S
857187 32/0.5/9.5 64 1/19 1 I
32/4/76;
868968 64/.05/9.5 >64* >4/76* ND ND
868972 32/4/76 64 >4/76* ND ND
869028 ND >64* >4/76* ND ND
875638 16/2/38 32 >4/76* D3.75 A
892483 ND >64* >4/76* ND ND
926439 32/0.125/2.38 64 0.25/4.75 0.75 A
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy K. pneumonia (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
848788 64/1/19 256* 16/304* 0.31 S
857147 8/0.125/2.38 32 16/304* 0.26 S
857187 32/1/19 128* 2/38 0.75 A
868968 64/2/38 256* 16/304* 0.38 S
868972 64/2/38 128* 16/304* 0.63 A
869028 64/2/38 256* 16/304* 0.38 S
870964 128/1/19 256* 4/76* 0.75 A
875638 16/2/38 64 16/304* 0.38 S
892483 64/2/38 256* 16/304* 0.38 S
926439 32/0.125/2.38 128* 0.5/9.5 0.5 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy P. aeruginosa (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
826882 16/0.25/4.75 64 >4/76* D3.28 S
880238 16/1/19 64 >4/76* D3.38 S
906939 8/2/38 64 >4/76* D3.38 S
926474 8/1/19 32 >4/76* D3.38 S
945543 16/0.125/1.19 32 0.125/1.19 1.5 I
945545 8/2/38 64 >4/76* D3.38 S
945748 16/0.5/9.5 64 >4/76* D3.31 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy P. aeruginosa (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
826882 32/0.5/9.5 128* 16/304* 0.28 S
880238 32/1/19 128* 16/304* 0.31 S
889058 4/1/19 128* 4/76* 0.28 S
906939 16/2/38 128* 16/304* 0.25 S
926474 16/2/38 64 16/304* 0.38 S
914881 4/1/19 128* 4/76* 0.28 S
924190 64/2/38 256* 8/152* 0.5 S
945543 4/1/19 128* 4/76* 0.28 S
945545 16/2/38 128* 16/304* 0.25 S
945748 32/0.5/9.5 128* 8/152* 0.31 S
PA01 4/0.5/9.5 32 2/38 0.38 S
pneumonia; TABLE 6 (utilizing the broth checkerboard assay) and TABLE 7 (utilizing the agar checkerboard assay) for P. aeruginosa. In these analyses. For FIC, synergy (S) was 0.5; additive (A) was 13.5-1;
indifferent (I) was >1-2; antagonistic (X) was >2); and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S. MIC comparator data was performed using the following known antibiotics: Amoxicillin/clavulanic acid, Cefotoxitin, Cefotaxime, Ceftazidime, Ceftriaxone, Piperacillin, Ampicillin, Merropenem, Polymixin B, Tobramycin, Amikacin, Ciprofloxacin (data not shown). The strains of E. coli in the comparator analyses included extended spectrum beta-lactamase (ESBL) producers based on phenotype (e.g., Amoxicillin/clavulanic acid resistance, or Cefotoxitin resistance), as well as carbapenem resistant, or quinolone resistant (15 strains). Strains of K. pneumonia in the comparator analyses were highly resistant to many of the clinical comparators, a number of these strains express ESBLs based on phenotype, and several were carbapenem, and quinolone resistant. Strains of K. pneumonia in the comparator analyses were highly resistant to commonly utilized clinical comparators, including 3rd-generation cephalosporins, carbapenems, aminoglycosides, and quinolones.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy Escherichia coli (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
846439 8/0.25/4.75 32 >4/76* D3.28 S
846446 0.25/0.06/1.25 2 >4/76* <0.13 S
846450 4/2/38 16 >4/76* <0.5 S
857021 8/2/38 32 >4/76* <0.5 S
863686 8/2/38 32 >4/76* <0.5 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy Escherichia coli (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
846439 16/0.5/9.5 64 8/152* 0.31 S
846446 1/0.125/2.38 4 8/152* 0.26 S
846450 8/2/38 32 8/152* 0.5 S
846455 4/1/19 128* 4/76* 0.28 S
847149 16/1/19 128* 4/76* 0.38 S
854535 64/1/19 128* 4/76* 0.75 A
854566 4/1/19 128* 4/76* 0.28 S
857021 16/2/38 64 8/152* 0.5 S
863078 4/1/19 128* 4/76* 0.28 S
863686 16/2/38 64 16/304* 0.38 S
ATCC 25922 0.12/0.25/4.75 16 1/19 0.26 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy K. pneumoniae (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
848788 ND >64* >4/76* ND ND
857147 4/0.06/1.19 16 >4/76* D3.26 S
857187 32/0.5/9.5 64 1/19 1 I
32/4/76;
868968 64/.05/9.5 >64* >4/76* ND ND
868972 32/4/76 64 >4/76* ND ND
869028 ND >64* >4/76* ND ND
875638 16/2/38 32 >4/76* D3.75 A
892483 ND >64* >4/76* ND ND
926439 32/0.125/2.38 64 0.25/4.75 0.75 A
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy K. pneumonia (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
848788 64/1/19 256* 16/304* 0.31 S
857147 8/0.125/2.38 32 16/304* 0.26 S
857187 32/1/19 128* 2/38 0.75 A
868968 64/2/38 256* 16/304* 0.38 S
868972 64/2/38 128* 16/304* 0.63 A
869028 64/2/38 256* 16/304* 0.38 S
870964 128/1/19 256* 4/76* 0.75 A
875638 16/2/38 64 16/304* 0.38 S
892483 64/2/38 256* 16/304* 0.38 S
926439 32/0.125/2.38 128* 0.5/9.5 0.5 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy P. aeruginosa (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
826882 16/0.25/4.75 64 >4/76* D3.28 S
880238 16/1/19 64 >4/76* D3.38 S
906939 8/2/38 64 >4/76* D3.38 S
926474 8/1/19 32 >4/76* D3.38 S
945543 16/0.125/1.19 32 0.125/1.19 1.5 I
945545 8/2/38 64 >4/76* D3.38 S
945748 16/0.5/9.5 64 >4/76* D3.31 S
Combo (ug/m1) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy P. aeruginosa (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
826882 32/0.5/9.5 128* 16/304* 0.28 S
880238 32/1/19 128* 16/304* 0.31 S
889058 4/1/19 128* 4/76* 0.28 S
906939 16/2/38 128* 16/304* 0.25 S
926474 16/2/38 64 16/304* 0.38 S
914881 4/1/19 128* 4/76* 0.28 S
924190 64/2/38 256* 8/152* 0.5 S
945543 4/1/19 128* 4/76* 0.28 S
945545 16/2/38 128* 16/304* 0.25 S
945748 32/0.5/9.5 128* 8/152* 0.31 S
PA01 4/0.5/9.5 32 2/38 0.38 S
[0097] Further synergy is identified in TABLE 8 (utilizing the broth checkerboard assay) against uUTI species. In these analyses FIC, synergy (S) was 0.5; additive (A) was 0.5-1; indifferent (I) was >1-2; antagonistic (X) was >2); and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S. Synergy was demonstrated with the novel combination described herein including synergistic activity against a preponderance of Proteus mirabilis, Staphylococcus saprophyticus, and Enterococcus faecalis strains. MIC comparator data was performed using the following known antibiotics: Nitrofurantoin, Fosfomycin, Co-trimoxazole, and Levofloxacin.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy P. mirabilis (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
1128681 1/0.0075/0.15 4 0.06/1.19 0.38 S
1124256 16/0.5/9.5 64 2/38 0.5 S
1184042 1/0.015/03 4 0.06/1.19 0.5 S
1071120 0.25/0.06/1.19 1 0.25/4.75 0.5 S
S. saprophyticus 1124324 8/0.125/2.38 32 0.5/9.5 0.5 S
1119421 8/0.125/2.38 32 0.5/9.5 0.5 S
16/0.125/2.38 1136894 64 0.25/4.75 D175 A
32R0.06/1.19 E. faecalis 10864321 0.125/0.5/9.5 32 >8/152* D104 S
1175598 8/2/38 32 >8/152* D138 S
1120278 8/0.25/4.75 64 0.5/9.5 0.63 A
1082155 8/2/38 32 >8/152* 0.38 S
1/0.125/2.38 1129099 4 0.25/4.75 D175 A
2/0.06/1.19
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy P. mirabilis (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
1128681 1/0.0075/0.15 4 0.06/1.19 0.38 S
1124256 16/0.5/9.5 64 2/38 0.5 S
1184042 1/0.015/03 4 0.06/1.19 0.5 S
1071120 0.25/0.06/1.19 1 0.25/4.75 0.5 S
S. saprophyticus 1124324 8/0.125/2.38 32 0.5/9.5 0.5 S
1119421 8/0.125/2.38 32 0.5/9.5 0.5 S
16/0.125/2.38 1136894 64 0.25/4.75 D175 A
32R0.06/1.19 E. faecalis 10864321 0.125/0.5/9.5 32 >8/152* D104 S
1175598 8/2/38 32 >8/152* D138 S
1120278 8/0.25/4.75 64 0.5/9.5 0.63 A
1082155 8/2/38 32 >8/152* 0.38 S
1/0.125/2.38 1129099 4 0.25/4.75 D175 A
2/0.06/1.19
[0098] Synergy is also identified in TABLE 9 (utilizing the agar checkerboard assay) against N.
gonorrhoeae. In these analyses, the agar dilution was performed utilizing GC
agar supplemented with Isovitalex, and 50 mg/L of D-glucose-6-phosphate. The FIC, synergy (S) was 0.5; additive (A) was 0.5-1;
indifferent (I) was >1-2; antagonistic (X) was >2); and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S. Synergy was demonstrated as well as an additive effect with the novel combination described herein against gonococci. MIC comparator data was performed using the following known antibiotics: Ceftriaxone, Azithromycin, Cefixime, Ciprofloxacin, Tetracycline, Pristinamycin, Solithromycin, and Delafloxacin. Pristinamycin was purified from capsules obtained in France; Solithromycin, and Delafloxacin were synthesized internally for comparison.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy N. gonorrhoeae (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
127781 4/0.5/9.5 16 1/19 0.75 A
127782 4/0.25/4.75 16 1/19 0.5 S
127783 4/0.5/9.5 16 1/19 0.75 A
127786 4/0.25/4.75 16 0.5/9.5 0.75 A
1117522 4/0.25/4.75 16 0.5/9.5 0.75 A
1117523 4/0.125/2.38 16 1/19 0.38 S
1117524 2/0.25/4.75 8 1/19 0.5 S
1117525 4/0.25/4.75 8 0.5/9.5 1 A
1117527 2/0.5/9.5 8 2/38 0.5 S
gonorrhoeae. In these analyses, the agar dilution was performed utilizing GC
agar supplemented with Isovitalex, and 50 mg/L of D-glucose-6-phosphate. The FIC, synergy (S) was 0.5; additive (A) was 0.5-1;
indifferent (I) was >1-2; antagonistic (X) was >2); and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S. Synergy was demonstrated as well as an additive effect with the novel combination described herein against gonococci. MIC comparator data was performed using the following known antibiotics: Ceftriaxone, Azithromycin, Cefixime, Ciprofloxacin, Tetracycline, Pristinamycin, Solithromycin, and Delafloxacin. Pristinamycin was purified from capsules obtained in France; Solithromycin, and Delafloxacin were synthesized internally for comparison.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy N. gonorrhoeae (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
127781 4/0.5/9.5 16 1/19 0.75 A
127782 4/0.25/4.75 16 1/19 0.5 S
127783 4/0.5/9.5 16 1/19 0.75 A
127786 4/0.25/4.75 16 0.5/9.5 0.75 A
1117522 4/0.25/4.75 16 0.5/9.5 0.75 A
1117523 4/0.125/2.38 16 1/19 0.38 S
1117524 2/0.25/4.75 8 1/19 0.5 S
1117525 4/0.25/4.75 8 0.5/9.5 1 A
1117527 2/0.5/9.5 8 2/38 0.5 S
[0099] Synergy was further demonstration using the broth checkerboard assay in TABLE 10 showing MIC for MRSA strains of S. aureus, many of which are associated with skin and skin structure infection (SSSI), and acute bacterial SSSI (ABSSSI). The breadth of the synergy against MRSA
with the novel combination described herein is supportive of an ABSSSI
indication. In these analyses FIC, synergy (S) was 0.5; additive (A) was 13.5-1; indifferent (I) was >1-2;
antagonistic (X) was >2);
and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI
susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy S. aureus (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
829025 1/0.015/0.3 4 0..06/1.19 0..5 S
829049 2/0.015/0.3 8 0..06/1.19 0.5 S
903887 2/0.015/0.3 8 0..06/1.19 0.5 S
920516 0.25/0.0078/0.15 2 0..06/1.19 0.5 S
920962 0.5/0.015/0.3 2 0.125/2.38 0.25 S
927596 2/0.03/0.6 8 0.125/2.38 0.38 S
938125 0.5/0.0078/0.15 4 0..06/1.19 0.5 S
953041 1/0.03/0.6 8 0.25/4.75 0.25 S
956270 0.5/0.015/0.3 28 0..06/1.19 0.5 S
956362 4/0.015/0.3 16 0..06/1.19 0.5 S
967287 2/0.0039/0.078 8 0..06/1.19 0.32 S
974980 2/0.03/0.6 8 0.125/2.38 0.5 S
979234 4/0.0078/0.15 16 0..06/1.19 0.38 S
1045190 0.5/0.015/0.3 2 0..06/1.19 0.5 S
with the novel combination described herein is supportive of an ABSSSI
indication. In these analyses FIC, synergy (S) was 0.5; additive (A) was 13.5-1; indifferent (I) was >1-2;
antagonistic (X) was >2);
and certain bacterial strains (*) were resistant to antibiotics as noted based on reported CLSI
susceptibility breakpoints: fosfomycin 64 p.g/ml, S; co-trimoxazole 2/38 p.g/ml, S.
Combo (ug/ml) Fosfomycin (F) DP/SM
FIC
(F/DP/SM) (first compound) (second compound Synergy S. aureus (1.1g/m1) (1.1g/m1) (1.1g/m1) S/A/I/X
829025 1/0.015/0.3 4 0..06/1.19 0..5 S
829049 2/0.015/0.3 8 0..06/1.19 0.5 S
903887 2/0.015/0.3 8 0..06/1.19 0.5 S
920516 0.25/0.0078/0.15 2 0..06/1.19 0.5 S
920962 0.5/0.015/0.3 2 0.125/2.38 0.25 S
927596 2/0.03/0.6 8 0.125/2.38 0.38 S
938125 0.5/0.0078/0.15 4 0..06/1.19 0.5 S
953041 1/0.03/0.6 8 0.25/4.75 0.25 S
956270 0.5/0.015/0.3 28 0..06/1.19 0.5 S
956362 4/0.015/0.3 16 0..06/1.19 0.5 S
967287 2/0.0039/0.078 8 0..06/1.19 0.32 S
974980 2/0.03/0.6 8 0.125/2.38 0.5 S
979234 4/0.0078/0.15 16 0..06/1.19 0.38 S
1045190 0.5/0.015/0.3 2 0..06/1.19 0.5 S
[00100] With the novel combination described herein, the bactericidal (killing) synergy was demonstrated against all strains shown in TABLE 11. As there is no published definition for bactericidal synergy, MIC metric was utilized. For the minimal bactericidal concentration (MBC, g/ml), TABLE 11 shows the lowest concentration providing a >3-log reduction within 24 hours of the first compound, the second compound, and the novel combination described herein.
Combo (1.1g/m1) Fosfomycin (F) DP/SM
(F/DP/SM) (first compound) (second compound) Bacteria (1.1g/m1) (1.1g/m1) (1.1g/m1) Staphylococcus aureus 1/0.5/9.5 128 2/38 (ATCC 29213 - MSSA) Staphylococcus aureus (ATCC 33591) (MRSA) Staphylococcus aureus (MG H-04) Staphylococcus aureus 16/0.5/9.5 128 2/38 (918019 - MRSA) Staphylococcus aureus (959797 - MRSA) Staphylococcus aureus 16/0.5/9.5 256 2/38 (USA-300 CDC - MRSA) Enterococcus faecalis 128/4/76 512 >16/304 (MGH-01) (VanA) Enterococcus faecalis (MGH-06) Enterococcus faecalis 64/4/76 512 >8/152 (ATCC 29212) Escherichia coli 0.12/0.5/9.5 32 2/38 (ATCC 25922) Escherichia coli 64/8/152 256 >8/152 (854535) Escherichia coli 64/0.25/4.75 256 2/38 (928017) Pseudomonas aeruginosa 64/4/76 >512 >8/152 (924190) Pseudomonas aeruginosa (985543)
Combo (1.1g/m1) Fosfomycin (F) DP/SM
(F/DP/SM) (first compound) (second compound) Bacteria (1.1g/m1) (1.1g/m1) (1.1g/m1) Staphylococcus aureus 1/0.5/9.5 128 2/38 (ATCC 29213 - MSSA) Staphylococcus aureus (ATCC 33591) (MRSA) Staphylococcus aureus (MG H-04) Staphylococcus aureus 16/0.5/9.5 128 2/38 (918019 - MRSA) Staphylococcus aureus (959797 - MRSA) Staphylococcus aureus 16/0.5/9.5 256 2/38 (USA-300 CDC - MRSA) Enterococcus faecalis 128/4/76 512 >16/304 (MGH-01) (VanA) Enterococcus faecalis (MGH-06) Enterococcus faecalis 64/4/76 512 >8/152 (ATCC 29212) Escherichia coli 0.12/0.5/9.5 32 2/38 (ATCC 25922) Escherichia coli 64/8/152 256 >8/152 (854535) Escherichia coli 64/0.25/4.75 256 2/38 (928017) Pseudomonas aeruginosa 64/4/76 >512 >8/152 (924190) Pseudomonas aeruginosa (985543)
[00101]
Bacericidal killing is demonstrated in FIGS. 2-4, against E. coli (FIG. 2), nitrofurantoin-resistant E. coli (FIG. 3), and S. aureus (FIG. 4). Antibiotic concentrations for E. coli (FIG. 2) were:
fosfomycin 2x (16 p.g/m1), 4x (32 p.g/m1); co-trimoxazole 2x (1/19 g/ml), 4x (2/38 lig g/m1); and the novel combination 2x (4/0.25/4.75 p.g/m1), and 4x (8/0.5/9.5 p.g/m1).
Antibiotic concentrations for S.
aureus (FIG. 4) were: fosfomycin 2x (64 p.g/m1), 4x (128 p.g/m1); co-trimoxazole 2x (1/19 p.g/m1), 4x (2/38 g/ml); and the novel combination 2x (16/0.25/4.75 p.g/m1), and 4x (32/0.5/9.5 p.g/m1).
Bacericidal killing is demonstrated in FIGS. 2-4, against E. coli (FIG. 2), nitrofurantoin-resistant E. coli (FIG. 3), and S. aureus (FIG. 4). Antibiotic concentrations for E. coli (FIG. 2) were:
fosfomycin 2x (16 p.g/m1), 4x (32 p.g/m1); co-trimoxazole 2x (1/19 g/ml), 4x (2/38 lig g/m1); and the novel combination 2x (4/0.25/4.75 p.g/m1), and 4x (8/0.5/9.5 p.g/m1).
Antibiotic concentrations for S.
aureus (FIG. 4) were: fosfomycin 2x (64 p.g/m1), 4x (128 p.g/m1); co-trimoxazole 2x (1/19 p.g/m1), 4x (2/38 g/ml); and the novel combination 2x (16/0.25/4.75 p.g/m1), and 4x (32/0.5/9.5 p.g/m1).
[00102] The described novel compositions (said combination of a first and second compounds or agents) were found to exhibit a synergy, and a growth inhibition well below breakpoint values. The unexpected values show synergy at unpredicted levels. Resistant breakpoints for the above first compound and second compound are provided below in TABLE 12, the data is based on CLSI MIC
breakpoint data (i.e. from the Clinical Laboratories Standards Institute) in comparison with data obtained from the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
Resistance breakpoints (g/ml) Fosfomycin DP with SM
CLSI >256 >4/76 ¨
EUCAST >32 >4/76
breakpoint data (i.e. from the Clinical Laboratories Standards Institute) in comparison with data obtained from the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
Resistance breakpoints (g/ml) Fosfomycin DP with SM
CLSI >256 >4/76 ¨
EUCAST >32 >4/76
[00103] Synergy with utilization of the composition described herein was found against both Gram negative bacteria, and Gram positive bacteria, which has not been found by other antimicrobial agents or combinations of antibiotic agents. In fact, the novel compositions described herein were effective against the most common Gram negative, and Gram positive bacteria independent of their resistance. In some embodiments, an FIC Index value was in the range of about 0.02 to 0.4 for E. coli, K. pneumoniae, and P. aeruginosa. The FIC Index value was in a range of about 0.07-0.25 for S. aureus. Synergy was found against S. aureus, including resistant strains of S. aureus, such as MRSA, which is a significant microorganism in hospital acquired bacterial pneumonia.
Further, the novel compositions described herein were active against strains that are resistant to the independent compounds that make up the composition when used on their own. As such, the novel compositions described herein are able to overcome the resistance problems previously found with utilization of its constituent components.
Further, the novel compositions described herein were active against strains that are resistant to the independent compounds that make up the composition when used on their own. As such, the novel compositions described herein are able to overcome the resistance problems previously found with utilization of its constituent components.
[00104] While the susceptibility breakpoint is 64 for fosfomycin alone and is 4/76 for a trimethoprim/sulfamethoxazole combination (e.g., when provided as co-trimoxazole), with the combinations described herein and as exhibited in the tables, MICs are at least four to eight fold below the breakpoints. To provide sustained and/or acceptable exposures of the combination described herein, it may, in some embodiments, be that fosfomycin is provided in an amount so as to have a concentration above 64 lighil, at least for about 70% of the time, or for greater than 70%
of the time. Similarly, it may be, in some embodiments, that the diaminopyridine (or its peak) is between about 5 and about 10 lighil, at least when administered, and/or for some time thereafter.
An example, the diaminopyridine may be above the MIC for about or greater than about 50% of the time. Taking the above into account, in a first example, a dosing regimen of a combination described herein may include about 1 g of fosfomycin, given three times per day (about 1 g per dose), with at least one of the diaminopyridine provided three times per day (at about 110 mg per dose), and/or the sulfonamide provided three times per day (at about 550 mg per dose).
of the time. Similarly, it may be, in some embodiments, that the diaminopyridine (or its peak) is between about 5 and about 10 lighil, at least when administered, and/or for some time thereafter.
An example, the diaminopyridine may be above the MIC for about or greater than about 50% of the time. Taking the above into account, in a first example, a dosing regimen of a combination described herein may include about 1 g of fosfomycin, given three times per day (about 1 g per dose), with at least one of the diaminopyridine provided three times per day (at about 110 mg per dose), and/or the sulfonamide provided three times per day (at about 550 mg per dose).
[00105] The described composition is able to reduce the MIC below the clinical breakpoints found for the individual components. This enables use of the novel compositions described herein against otherwise multi-drug resistant bacteria, including multi-drug resistant E. coli, multi-drug resistant P. aeruginosa, and multi-drug resistant S. aureus, as examples.
Thus, with the described combinations and the low MIC values (low MIC within a "susceptible" range, and/or low MIC that is well below the accepted "susceptible" range) there will be better outcomes.
With the number of strains, and types of strains showing susceptibility to the combinations described herein, lower doses (of each component, or of one or more of the components) will be possible with the combinations described herein (e.g., for treatment against, killing of, and/or inhibition of growth of the susceptible microorganisms). With the number of strains, and types of strains, showing susceptibility to the combinations described herein, shorted treatment duration (of each component, or of one or more of the components) will be possible with the combinations described herein (e.g., for treatment against, killing of, and/or inhibition of growth of the susceptible microorganisms). With the number of strains, and types of strains, showing susceptibility to the combinations described herein, a shorter median time to defervescence will be possible with the combinations described herein (when administered for treatment against, killing of, and/or inhibition of growth of the susceptible microorganisms).
Thus, with the described combinations and the low MIC values (low MIC within a "susceptible" range, and/or low MIC that is well below the accepted "susceptible" range) there will be better outcomes.
With the number of strains, and types of strains showing susceptibility to the combinations described herein, lower doses (of each component, or of one or more of the components) will be possible with the combinations described herein (e.g., for treatment against, killing of, and/or inhibition of growth of the susceptible microorganisms). With the number of strains, and types of strains, showing susceptibility to the combinations described herein, shorted treatment duration (of each component, or of one or more of the components) will be possible with the combinations described herein (e.g., for treatment against, killing of, and/or inhibition of growth of the susceptible microorganisms). With the number of strains, and types of strains, showing susceptibility to the combinations described herein, a shorter median time to defervescence will be possible with the combinations described herein (when administered for treatment against, killing of, and/or inhibition of growth of the susceptible microorganisms).
[00106] With the described composition using the first compound and the second compound, such as ones identified in the tables, the frequency of spontaneous mutants resistant to said novel composition was representatively assessed, and found to be 1..8 x 104 as compared with 6.33 x 10-6 for fosfomycin alone or 2.67 x 10-9 for co-trimoxazole alone or 3.40 x 108 for nitrofurantoin. The spontaneous mutational frequency (SMF; resistance) was calculated as the number of resistant colonies observed divided by the total inoculum. The substantially lower SMF
for the novel combination described herein indicates a lower potential for resistance evolution as compared with the individual components, or the nitrofurantoin comparator. Without being bound by theory, it is suggested that in addition to the substantially lower SMF and in view of the synergy described herein, susceptibility breakpoints with the described compositions may not have to change significantly over time. In some embodiments, susceptibility breakpoints with the described compositions will not have to change significantly.
for the novel combination described herein indicates a lower potential for resistance evolution as compared with the individual components, or the nitrofurantoin comparator. Without being bound by theory, it is suggested that in addition to the substantially lower SMF and in view of the synergy described herein, susceptibility breakpoints with the described compositions may not have to change significantly over time. In some embodiments, susceptibility breakpoints with the described compositions will not have to change significantly.
[00107] With the described compositions, and without being bound by theory, but in view, in part on the substantially lower SMF, and, in part, on the synergy, there will be an infrequent selection of resistant bacterial strains with the combinations described herein. The infrequent selection will also be infrequent at even low concentrations of the combinations described herein.
[00108] With the described novel compositions an MIC90 16 p.g/mL was identified for certain important Gram negative bacteria. For such strains, a representative dosing regimen of the novel composition against, for example, E. coli strains, such as those tested in the tables above may include 0.03-16 p.g/mL of the first compound, and 0.61-38 p.g/mL, and 0.03-2 p.g/mL of the second compound, which comprises two individual components of DP, and SM.
[00109] With the described novel compositions MICs 64 p.g/mL were identified for other, and most of the remaining important Gram negative bacteria. For such strains, a representative dosing regimen of the novel composition against, for example, P. aeruginosa strains, such as those tested in the tables above may include 2-32 p.g/mL of the first compound, and 0.125-2 p.g/mL, and 0.219-38 p.g/mL of the second compound, which comprises two individual components of DP, and SM.
[00110] In view of prior safety analysis for components that may make up the compositions described herein, the combinations described herein will likely include amounts or doses of each of the components that are about or less than the amounts or doses of each of the components (when used individually) found to be safe when provided to a subject in need thereof.
[00111] As shown, the combination described herein provides excellent Gram-positive activity, and Gram-negative activity, thereby offering a broadened spectrum, with synergistic potency.
Further, the combination described herein provides efficacy against a wide variety of infectious organisms, including parasites. The combination may be selected to have a therapeutic effect based on the sulfonamide(s) and/or the diaminopyridine(s) that are in the combination, in which certain sulfonamides and/or diaminopyridines exhibit greater or lesser antiparasitic activity in addition to their antibacterial activity. The combination described herein is effective against strains resistant to one or more of the components in the described composition. The combination described herein is effective against strains resistant to existing drugs or agents that are currently used with some effectiveness in certain individuals in need thereof. The spectrum of activity, as provided with the described composition, is supportive of use with many infections, such as those of the urinary tract, respiratory tract, and skin and skin structures, including acute bacterial skin and skin structure infections, and sexually transmitted infections, and related infections or diseases. The bactericidal activity as provided with the described composition is supportive of use at reduced concentrations as compared with current use of the independent components when used for current indications as an antibiotic for bacterial infections, including infections of the urinary tract, respiratory tract, and skin a skin structure, including acute bacterial skin, and skin structure infections, and certain sexually transmitted diseases, and related infections. The very low frequency of spontaneous mutational frequency with the combination described herein is highly indicative of a much reduced potential for resistance with the compositions described herein. In some embodiments, the described combination may be administered in a lower dose while still providing efficacy. In some embodiments, the described combination may be administered at a higher dose while remaining safe for use. In one or more embodiments, the described combination provides an improved therapeutic index of the combination while not enhancing general toxicity.
Further, the combination described herein provides efficacy against a wide variety of infectious organisms, including parasites. The combination may be selected to have a therapeutic effect based on the sulfonamide(s) and/or the diaminopyridine(s) that are in the combination, in which certain sulfonamides and/or diaminopyridines exhibit greater or lesser antiparasitic activity in addition to their antibacterial activity. The combination described herein is effective against strains resistant to one or more of the components in the described composition. The combination described herein is effective against strains resistant to existing drugs or agents that are currently used with some effectiveness in certain individuals in need thereof. The spectrum of activity, as provided with the described composition, is supportive of use with many infections, such as those of the urinary tract, respiratory tract, and skin and skin structures, including acute bacterial skin and skin structure infections, and sexually transmitted infections, and related infections or diseases. The bactericidal activity as provided with the described composition is supportive of use at reduced concentrations as compared with current use of the independent components when used for current indications as an antibiotic for bacterial infections, including infections of the urinary tract, respiratory tract, and skin a skin structure, including acute bacterial skin, and skin structure infections, and certain sexually transmitted diseases, and related infections. The very low frequency of spontaneous mutational frequency with the combination described herein is highly indicative of a much reduced potential for resistance with the compositions described herein. In some embodiments, the described combination may be administered in a lower dose while still providing efficacy. In some embodiments, the described combination may be administered at a higher dose while remaining safe for use. In one or more embodiments, the described combination provides an improved therapeutic index of the combination while not enhancing general toxicity.
[00112] Without being bound by theory, the synergism found with the novel compositions described herein may be related to specific inhibition of peptidoglycan (cell wall) synthesis in addition to a synergistic inhibition of a pathway leading to essential metabolites necessary for peptidoglycan synthesis rendering bacteria or other microorganisms highly susceptible to the novel compositions disclosed herein. In view of said mechanism of action of said novel composition, said novel composition should be effective against many or most clinically relevant Gram negative as well as Gram positive bacteria independent of the bacterial resistance profiles.
Further, it is expected that there will be a reduced risk of use with said novel compositions in view of their known safety profiles showing they are well tolerated, and have safe usage when provided individually. Moreover, with lower dosing levels, as may be provided with the novel compositions described herein, there will be fewer safety concerns. A favorable spectrum against other multidrug resistant Gram negative, and Gram positive bacteria is provided expected to be due in part to the highly synergistic interaction found with the novel composition described herein.
Further, it is expected that there will be a reduced risk of use with said novel compositions in view of their known safety profiles showing they are well tolerated, and have safe usage when provided individually. Moreover, with lower dosing levels, as may be provided with the novel compositions described herein, there will be fewer safety concerns. A favorable spectrum against other multidrug resistant Gram negative, and Gram positive bacteria is provided expected to be due in part to the highly synergistic interaction found with the novel composition described herein.
[00113]
Providing the combination as described above, such as sequentially, or concomitantly, to a subject in need will preferably include providing all the components of the composition so that there is overlapping exposure with regard to each of the components. Providing the combination as described will preferably include having each of the components in sufficient amounts at a similar schedule or an overlapping schedule (same or overlapping times), or at or near maximal amounts at a similar a schedule or an overlapping schedule (same or overlapping times), whether or not the components are in a same formulation.
Providing the combination as described above, such as sequentially, or concomitantly, to a subject in need will preferably include providing all the components of the composition so that there is overlapping exposure with regard to each of the components. Providing the combination as described will preferably include having each of the components in sufficient amounts at a similar schedule or an overlapping schedule (same or overlapping times), or at or near maximal amounts at a similar a schedule or an overlapping schedule (same or overlapping times), whether or not the components are in a same formulation.
[00114] In one or more embodiments, a formulation, or the combination as described herein, may be provided once a day. In some embodiments, a formulation, or the combination as described herein may be provided twice daily. In one or more embodiments, a formulation, or the combination as described herein may be provided three times a day. In one or more embodiments, a formulation, or the combination as described herein may be provided four times a day, or at least one of the components is provided up to four times per day. Fosfomycin, having a short half-life, may, in some embodiments, be provided more than once per day, or at least in divided doses, two times a day, or three time a day, or four times a day. In one or more embodiments, a total daily amount of the fosfomycin may be in an amount in a range of about 0.5 g (per day) to about 6 g (per day). In one or more embodiments, a total daily amount of the sulfonamide (e.g., sulfamethoxazole) may be in an amount in a range of about 400 mg (per day) to about 3200 mg (per day). In one or more embodiments, a total daily amount of the diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) may be in an amount in a range of about 80 mg (per day) to about 500 mg (per day).
[00115]
Additional representative dosing examples are provided. For example, a dosing may include a twice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 750 mg (each dose, 2 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 2 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 80 mg (each dose, 2 times/day). In another example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 333 mg (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 267 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 53 mg (each dose, 3 times/day). In another example, a dosing may include once daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 4 g (one dose/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 1600 mg (one dose/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 250 mg (one dose/day). In a further example, a dosing may include a twice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 2 g (each dose, 2 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 800 mg (each dose, 2 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 125 mg (each dose, 2 times/day). In still another example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 1.33 g (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 75 mg (each dose, 3 times/day). In yet another example, a dosing may include a twice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 1.5 g (each dose, 2 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 2 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 80 mg (each dose, 2 times/day). In still another example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 1 g (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 167 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 54 mg (each dose, 3 times/day). In another example, a dosing may include once daily dosing of fosfomycin provided in an amount of up to about or about 3 g (one dose/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided twice daily in an amount of up to about or about 400 mg (two doses/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided twice daily in an amount of up to about or about 80 mg (two doses/day). In a further example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 500 mg (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 75 mg (each dose, 3 times/day). In another example, a dosing may include twice daily dosing of fosfomycin provided in an amount of up to about or about 1 g (two doses/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided twice daily in an amount of up to about or about 800 mg (two doses/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided twice daily in an amount of up to about or about 125 mg (two doses/day). Of course, additional dosing schedules are contemplated and/or suitable.
Additional representative dosing examples are provided. For example, a dosing may include a twice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 750 mg (each dose, 2 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 2 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 80 mg (each dose, 2 times/day). In another example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 333 mg (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 267 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 53 mg (each dose, 3 times/day). In another example, a dosing may include once daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 4 g (one dose/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 1600 mg (one dose/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 250 mg (one dose/day). In a further example, a dosing may include a twice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 2 g (each dose, 2 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 800 mg (each dose, 2 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 125 mg (each dose, 2 times/day). In still another example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 1.33 g (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 75 mg (each dose, 3 times/day). In yet another example, a dosing may include a twice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 1.5 g (each dose, 2 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 2 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 80 mg (each dose, 2 times/day). In still another example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 1 g (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 167 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 54 mg (each dose, 3 times/day). In another example, a dosing may include once daily dosing of fosfomycin provided in an amount of up to about or about 3 g (one dose/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided twice daily in an amount of up to about or about 400 mg (two doses/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided twice daily in an amount of up to about or about 80 mg (two doses/day). In a further example, a dosing may include a thrice daily dosing provided to a subject in need, in which fosfomycin is provided in an amount of up to about or about 500 mg (each dose, 3 times/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided in an amount of up to about or about 400 mg (each dose, 3 times/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided in an amount of up to about or about 75 mg (each dose, 3 times/day). In another example, a dosing may include twice daily dosing of fosfomycin provided in an amount of up to about or about 1 g (two doses/day), and in which the sulfonamide (e.g., sulfamethoxazole) is provided twice daily in an amount of up to about or about 800 mg (two doses/day), and/or diaminopyridine (e.g., trimethoprim, and/or pyrimethamine) is provided twice daily in an amount of up to about or about 125 mg (two doses/day). Of course, additional dosing schedules are contemplated and/or suitable.
[00116] The duration of the combination (in a single formulation or when said components are provided so that there is overlapping exposure of the components) may be from five days to 10 days, or may be from 10 days to 14 days. The duration of the combination may be from 1 day and up to about 21 days, or any length therebetween, the length of time, depending in part on the severity of the infection.
[00117] The novel compositions described herein may be provided for a number of uses, including but not limited to topical, oral, and parenteral (IV) use or for inhalation. Dosage forms of the novel compositions include pharmaceutically acceptable forms that provide effective treatment against one or more bacterial infections. Said forms may include pharmaceutically acceptable salts, esters or prodrugs thereof. Said forms may further include a pharmaceutically acceptable base addition salt, which refers to those salts that retain the biological effectiveness, and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Said forms may also include a pharmaceutically acceptable acid addition salt, which refers to those salts that retain the biological effectiveness, and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids. Said dosage forms will include dosages with acceptable side effect profiles when administered to a subject in need thereof. In one or more embodiments, the novel compositions described herein are provided as a pharmaceutical composition, which refers to a formulation containing each component of the composition along with a medium generally accepted in the art for the delivery of the novel composition on its whole or in its parts. For effective use, the pharmaceutical composition will be a biologically active composition, delivered to a subject in need thereof, such as a mammal, for example, humans. The medium will include any pharmaceutically acceptable carrier(s), diluent(s), and/or excipient(s).
[00118] In many embodiments, the novel composition will be provided at a therapeutically effective amount, which refers to that amount of the novel composition on its whole which, when administered to a subject in need thereof, is sufficient to effect treatment of a symptom, a condition, or a disease of interest in the subject or as presented by the subject. The amount of an antibiotic composition of the invention which constitutes a "therapeutically effective amount" will vary depending on the antibiotic composition, the disease or condition, and its severity, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge, and to this disclosure. The therapeutically effective amount may be modified by pharmacokinetic, and pharmacodynamic analysis as is understood in the field.
In some embodiments, the novel composition may be provided prophylactically or preventatively or protectively, which may, in some instances, be at or below a therapeutically effective amount. A
representative example of pharmacokinetic parameters is provided in TABLE 13.
diaminopyridine sulfonamide (e.g., Fosfomycin (e.g., trimethoprim) sulfamethoxazole) Dose 3000 mg 720 mg 3600 mg Tmax 2 hrs 2 hrs 4 hrs Cmax 26.1 p.g/mL 8.5 p.g/mL 120 p.g/mL
T 1/2 5.7 hrs kel (elimination rate 0.122 hrs 0.08 hrs 0.08 to 1 hr constant) Cmax/dose 0.0087 mg 0.012 mg 0.033 mg
In some embodiments, the novel composition may be provided prophylactically or preventatively or protectively, which may, in some instances, be at or below a therapeutically effective amount. A
representative example of pharmacokinetic parameters is provided in TABLE 13.
diaminopyridine sulfonamide (e.g., Fosfomycin (e.g., trimethoprim) sulfamethoxazole) Dose 3000 mg 720 mg 3600 mg Tmax 2 hrs 2 hrs 4 hrs Cmax 26.1 p.g/mL 8.5 p.g/mL 120 p.g/mL
T 1/2 5.7 hrs kel (elimination rate 0.122 hrs 0.08 hrs 0.08 to 1 hr constant) Cmax/dose 0.0087 mg 0.012 mg 0.033 mg
[00119] Treating a subject may be treating a subject in need thereof or treating a subject preventatively or protectively. Generally, treating as described herein, and a treatment as described herein may include treatment of a symptom, or a condition, or a disease of interest, or an infection as presented by a subject, or is defending against a condition or a disease or a symptom. Treatment may include but is not limited to: (i) preventing the symptom or disease or condition from occurring in a subject (such as when such subject is predisposed to the disease or condition, and has not yet been diagnosed or is not yet symptomatic; (ii) inhibiting a symptom or disease or condition (e.g., arresting its development; (iii) relieving a symptom or disease or condition (e.g., causing regression of the symptom disease or condition; or (iv) stabilizing the symptom or disease or condition.
[00120]
Embodiments described herein further include treating one or more conditions or symptoms (e.g., infections, and/or diseases associate with one or more infections caused by or considered to be associated with a microbe, including bacteria described previously). Treating may including when presenting with symptoms or prior to presenting with symptoms.
Microbial infections include but are not limited to wound infections, respiratory infections, systemic infections, skin infection, sexually transmitted diseases, and related infections, gastrointestinal, urogenital infections, pneumonia, tuberculosis, gonorrhea, syphilis, sepsis, meningitis, cholera, and diarrhea associated with a microbial infection. Treating may include prophylaxis, therapy, and/or cure.
Treating of a subject may involve reducing infection, preventing infection, and/or delaying or slowing the onset of an infection or an associated condition, disease, or disorder (e.g. the symptoms associated with the disease, condition, or disorder). In some embodiments, the infection may be associated with antibiotic resistant bacteria.
Embodiments described herein further include treating one or more conditions or symptoms (e.g., infections, and/or diseases associate with one or more infections caused by or considered to be associated with a microbe, including bacteria described previously). Treating may including when presenting with symptoms or prior to presenting with symptoms.
Microbial infections include but are not limited to wound infections, respiratory infections, systemic infections, skin infection, sexually transmitted diseases, and related infections, gastrointestinal, urogenital infections, pneumonia, tuberculosis, gonorrhea, syphilis, sepsis, meningitis, cholera, and diarrhea associated with a microbial infection. Treating may include prophylaxis, therapy, and/or cure.
Treating of a subject may involve reducing infection, preventing infection, and/or delaying or slowing the onset of an infection or an associated condition, disease, or disorder (e.g. the symptoms associated with the disease, condition, or disorder). In some embodiments, the infection may be associated with antibiotic resistant bacteria.
[00121]
Formulations prepared with the described compositions may include those suitable for oral, nasal, topical (including buccal, and sublingual), intravenous, rectal, vaginal, and/or parenteral administration. The formulations may conveniently be presented in unit dosage form, and may be prepared by any methods well known in the pharmacy field. The amount of active ingredient which can be combined with additional components, and/or a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, and other factors. The amount of active ingredient that can be combined with or without a carrier material to produce a single dosage form will, in many embodiments, generally be that amount of the compound, and/or the composition which produces a therapeutic effect.
Generally, this amount will range from about 1% to about 99% of active ingredient, or from about 5%
to about 80%, or any amount therein.
Formulations prepared with the described compositions may include those suitable for oral, nasal, topical (including buccal, and sublingual), intravenous, rectal, vaginal, and/or parenteral administration. The formulations may conveniently be presented in unit dosage form, and may be prepared by any methods well known in the pharmacy field. The amount of active ingredient which can be combined with additional components, and/or a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, and other factors. The amount of active ingredient that can be combined with or without a carrier material to produce a single dosage form will, in many embodiments, generally be that amount of the compound, and/or the composition which produces a therapeutic effect.
Generally, this amount will range from about 1% to about 99% of active ingredient, or from about 5%
to about 80%, or any amount therein.
[00122] The described compositions may be provided as an injectable or parenteral formulation.
Such compositions will include an effective amount of an excipient. The excipient will have one or more of the following functionalities: soluble; stabilization (e.g.
antioxidant); anti-microbial preservation; impart tonicity (with a goal of achieving isotonicity); bulking agent. In some embodiments, the described compositions will be available in a sterile, pyrogen-free solution or as a lyophilized powder for reconstitution. They may be provided as single-use vials or formulated in, e.g., USP water for injection, or as a lyophilized powder, such as in an amount that will be reconstituted with dextrose for intravenous administration.
Such compositions will include an effective amount of an excipient. The excipient will have one or more of the following functionalities: soluble; stabilization (e.g.
antioxidant); anti-microbial preservation; impart tonicity (with a goal of achieving isotonicity); bulking agent. In some embodiments, the described compositions will be available in a sterile, pyrogen-free solution or as a lyophilized powder for reconstitution. They may be provided as single-use vials or formulated in, e.g., USP water for injection, or as a lyophilized powder, such as in an amount that will be reconstituted with dextrose for intravenous administration.
[00123] For oral administration, the described composition may be for immediate or sustained release (e.g., provided as granules, and/or by layering, such as a multi-layered tablet or capsule having granules therein, in which there are different release profile for each layer and/or granule, such as fast release in one layer (or set of granules), and delayed release in the other(s) which can be modulated to enable the ultimate or desired bioavailability). A binary combination may be provided into one multilayered film-coated tablet and/or capsule (as well as other suitable forms). An oral formulation may include a plurality of granules or plurality of layers or plurality of components each having its own unique release characteristics in order to maximize release and/or to ensure sufficient overlap and exposure of the components at the site of infection. A
carrier may also be included for increasing AUC of one or more layers and/or set of granules, as described above.
Layering, hot-melt extrusion (HME), granulation, and/or lipid drug delivery are exemplary means used to provide the described composition for oral administration. The described compositions may further comprise one or more of the following: tablet and/or capsular coating, disintegrant, surfactant, lubricant, glidant, anti-adherent, and corn starch anti-sticking agent.
carrier may also be included for increasing AUC of one or more layers and/or set of granules, as described above.
Layering, hot-melt extrusion (HME), granulation, and/or lipid drug delivery are exemplary means used to provide the described composition for oral administration. The described compositions may further comprise one or more of the following: tablet and/or capsular coating, disintegrant, surfactant, lubricant, glidant, anti-adherent, and corn starch anti-sticking agent.
[00124] Also provided are kits including one or more pharmaceutical compositions described herein. A kit may include one or more additional agents, compounds with compositions described herein. The different components of the kit may be provided in different containers. The kit may be compartmentalized to receive the containers in close confinement. The kit may also contain instructions for using the described compositions with accompanying components. Illustrative examples of containers for said kits include, but are not limited to, small glass containers, plastic containers, composite containers, or strips of plastic or paper. Containers may be those that allow a worker to efficiently transfer reagents or components from one compartment to another compartment. Such containers may also one that will accept a compound or compositions described herein, and /or may accept a resuspending solution. Said compositions being in any one or more of a powder (e.g. a lyophilized powder), precipitate, granules, tablet, gel or liquid form, as examples.
Compositions described herein or one or more of the components that make us the described compositions may be provided in the same or different forms in a single kit, and may be provided in the same or different containers.
Compositions described herein or one or more of the components that make us the described compositions may be provided in the same or different forms in a single kit, and may be provided in the same or different containers.
[00125] In one or more embodiments, DP, and SM may be prepared as a blend, by mixing the requisite ingredients as is known in the art. An organic solvent which is miscible with water (e.g., glycofurol or a polyethyleneglycol) may also be added during the preparation.
The mixture may further comprise fosfomycin or its precursor or requisite ingredients.
Alternatively, the DP, and SM
may remain independent, and be prepared independently from the fosfomycin, in which case said DP, and/or the SM, and the fosfomycin may be co-administered (sequentially, or concomitantly).
The mixture may further comprise fosfomycin or its precursor or requisite ingredients.
Alternatively, the DP, and SM
may remain independent, and be prepared independently from the fosfomycin, in which case said DP, and/or the SM, and the fosfomycin may be co-administered (sequentially, or concomitantly).
[00126] Said aqueous compositions (or the DP, and/or SM and the fosfomycin independently) may be dried using known techniques, including freeze-drying, spray-drying.
Precipitates may also be prepared from the aqueous compositions using methods known in the field, and dried, such as under vacuum. The resulting dry compositions, which are also a part of what is disclosed herein, may be reconverted, when desired (with or without sterilization, such as after sterilization) into solutions (e.g. injection solutions) by the addition of water or other suitable liquid for dissolving said dry components.
Precipitates may also be prepared from the aqueous compositions using methods known in the field, and dried, such as under vacuum. The resulting dry compositions, which are also a part of what is disclosed herein, may be reconverted, when desired (with or without sterilization, such as after sterilization) into solutions (e.g. injection solutions) by the addition of water or other suitable liquid for dissolving said dry components.
[00127] The compositions described herein may be used, in addition to use as injectable solutions, by other means of administration in which said combination in solution form should be used.
[00128] The compositions described herein may be used by any means of administration in which said combination in solid form should be used.
[00129] In another embodiment, the components are blended in dry form, and granulated by means known in the art (such as with a binding agent, polymeric component, etc.) to form a tablet or a pressed composition.
[00130] The compositions described herein may also be sterilized by means of known techniques which are usual in the preparation of parenteral administration forms as, for example, heat sterilization or sterile filtration.
[00131]
Embodiments described herein include treating subjects infected with, and/or subjects at risk of developing, a microbial infection, including a drug-resistant microbial infection. A subject may be a mammal, including an animal or other multicellular organism. A
subject may be a human.
A subject may be a pet or a farm animal.
Embodiments described herein include treating subjects infected with, and/or subjects at risk of developing, a microbial infection, including a drug-resistant microbial infection. A subject may be a mammal, including an animal or other multicellular organism. A
subject may be a human.
A subject may be a pet or a farm animal.
[00132] Several methods for killing the microorganisms are included with the inventions described herein. One or more methods include directly killing the microorganisms. The microorganisms may include Gram-positive bacteria. The microorganisms may include parasites.
The microorganisms may include microorganisms considered resistance to alternative antimicrobial agents. The microorganisms may include microorganisms considered resistant to one of more of the ingredients used in the compositions described herein (e.g., at least one first compound or agent, and at least one second compound or agent). One or more methods may include killing the microorganisms in a subject in need thereof, the method comprising providing at least one form of the composition described herein (having at least one first compound or agent, and at least one second compound or agent). The method further comprises administering the at least one form of the composition described herein to the subject in a dose sufficient to kill or directly kill the microorganism. The method may further comprise administering the at least one form of the composition described herein to the subject in a dose and for a duration sufficient to kill or directly kill the microorganism. In addition, or as an alternative, the method may comprise administering the at least one form of the composition described herein to the subject in a dose and for a duration sufficient to control infection caused by or attributed to the microorganism.
In addition, or as an alternative, the method may comprise administering the at least one form of the composition described herein to the subject in a dose and for a duration sufficient to suppress an infection caused by or attributed to the microorganism.
The microorganisms may include microorganisms considered resistance to alternative antimicrobial agents. The microorganisms may include microorganisms considered resistant to one of more of the ingredients used in the compositions described herein (e.g., at least one first compound or agent, and at least one second compound or agent). One or more methods may include killing the microorganisms in a subject in need thereof, the method comprising providing at least one form of the composition described herein (having at least one first compound or agent, and at least one second compound or agent). The method further comprises administering the at least one form of the composition described herein to the subject in a dose sufficient to kill or directly kill the microorganism. The method may further comprise administering the at least one form of the composition described herein to the subject in a dose and for a duration sufficient to kill or directly kill the microorganism. In addition, or as an alternative, the method may comprise administering the at least one form of the composition described herein to the subject in a dose and for a duration sufficient to control infection caused by or attributed to the microorganism.
In addition, or as an alternative, the method may comprise administering the at least one form of the composition described herein to the subject in a dose and for a duration sufficient to suppress an infection caused by or attributed to the microorganism.
[00133] One or more methods described herein may include killing or inhibiting growth of microorganisms present on a surface or within an object or a subject in need thereof, the method comprising contacting the microorganisms with a formulation comprising an effective amount of one of the compositions described herein, wherein contacting results in killing or in inhibiting growth of the microorganism, the formulation comprising at least a pharmaceutically acceptable fosfomycin, and one or more of a pharmaceutically acceptable sulfonamide and/or a pharmaceutically acceptable diaminopyridine. The microorganism may be a bacteria. The microorganism may be a parasite. The microorganism may be resistant to one or more of the components that make of the formulation. The fosfomycin may be in the form of a pharmaceutically acceptable salt, ester, or prodrug, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the microorganism. The sulfonamide may be one or more sulfonamide in the form of a pharmaceutically acceptable salt, ester, or prodrug, or an analog or derivative thereof, any of which have any of which have inhibitory activity in folic acid metabolism. The diaminopyridine may be one or more diaminopyridine in the form of a pharmaceutically acceptable salt, ester, or prodrug, or an analog or derivative thereof, any of inhibit dihydrofolate reductase. The effective amount may be an amount of at least one of the fosfomycin, the diaminopyridine, and/or the sulfonamide that is less than an amount indicated as a therapeutically effective amount when used alone.
[00134] As used herein, and in the appended claims, the singular forms "a," "and," and "the"
include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" or to "a composition" includes a plurality of such agents or compositions, and equivalents thereof known to those skilled in the art, and so forth. It is understood that the term "comprising"
(and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude embodiments wherein, for example, any composition of matter, composition, method, or process, or the like, described herein may "consist of" or "consist essentially of" the described features.
include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" or to "a composition" includes a plurality of such agents or compositions, and equivalents thereof known to those skilled in the art, and so forth. It is understood that the term "comprising"
(and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude embodiments wherein, for example, any composition of matter, composition, method, or process, or the like, described herein may "consist of" or "consist essentially of" the described features.
[00135] Although representative processes, and articles have been described in detail herein, those skilled in the art will recognize that various substitutions and modifications may be made without departing from the scope, and spirit of what is described, and defined by the appended claims.
Claims (40)
1. A method of inhibiting growth of a susceptible microorganism, or killing the susceptible microorganism, the method comprising:
providing a therapeutically effective amount of a composition to the microorganism, the composition comprising in a single formulation a combination of at least three compounds or agents comingling, the combination of the at least three compounds or agents comprising at least a fosfomycin, at least one sulfonamide, and at least one diaminopyridine, the combination of the at least three compounds or agents inhibiting growth of the microorganism, or killing the susceptible microorganism, the fosfomycin being a pharmaceutically acceptable salt, or ester, or an analog, or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, and wherein a mean inhibitory concentration of the composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for each of the at least three compounds or agents when the at least three compounds or agents are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least three compounds or agents individually.
providing a therapeutically effective amount of a composition to the microorganism, the composition comprising in a single formulation a combination of at least three compounds or agents comingling, the combination of the at least three compounds or agents comprising at least a fosfomycin, at least one sulfonamide, and at least one diaminopyridine, the combination of the at least three compounds or agents inhibiting growth of the microorganism, or killing the susceptible microorganism, the fosfomycin being a pharmaceutically acceptable salt, or ester, or an analog, or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, and wherein a mean inhibitory concentration of the composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for each of the at least three compounds or agents when the at least three compounds or agents are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least three compounds or agents individually.
2. The method of claim 1, wherein the at least one sulfonamide includes analogs, and derivatives thereof, any of which have inhibitory activity in the synthesis of dihydrofolate, or is sulfamethoxazole.
3. The method of any one of claim 1 or claim 2, wherein the at least one diaminopyridine includes an analog, or derivative thereof, any of which inhibit dihydrofolate reductase, or is trimethoprim.
4. The method of any one of claims 1 to 3, wherein the at least one diaminopyridine is or includes a pyrimethamine.
5. The method of any one of claims 1 to 4, wherein the susceptible microorganism is one suspected to cause a bacterial infection selected from the group consisting of a gastrointestinal infection, genitourinary infection, respiratory infection, skin infection, systemic infection, wound infection, and sexually transmitted infection.
6. The method of any one of claims 1 to 5, wherein the at least one diaminopyridine is or includes an iclaprim.
7. The method of any one of claims 1 to 6, wherein the susceptible microorganism is considered resistant to one or more of the fosfomycin, the at least one sulfonamide, and the at least one diaminopyridine.
8. The method of any one of claims 1 to 7, wherein the susceptible microorganism resides in or on a subject, and the composition is for administering to the subject.
9. The method of any one of claims 1 to 8, wherein the susceptible microorganism resides in a subject, and the composition is provided to the subject by a route selected from the group consisting of oral, parenteral, topical, ocular, intramuscular, transdermal, nasal, and combinations thereof.
10. Use of a composition to treat a bacterial infection in a subject in need thereof, wherein the composition comprising in a single formulation a combination of at least three compounds or agents comingling, the at least three compounds or agents comprising at least a fosfomycin, at least one sulfonamide, and at least one diaminopyridine, the fosfomycin being a pharmaceutically acceptable salt, or ester, or an analog, or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the at least one susceptible microorganism, wherein a mean inhibitory concentration of the composition when provided for inhibiting growth of the at least one susceptible microorganism is below a resistance breakpoint identified for each of the at least three compounds or agents when the at least three compounds or agents are individually and independently provided for inhibiting growth of the at least one susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least three compounds or agents individually.
11. The use of claim 10, wherein the at least one sulfonamide is sulfamethoxazole.
12. The use of any one of claim 10 or claim 11, wherein the at least one diaminopyridine is trimethoprim.
13. The use of any one of claims 10 to 12, wherein the at least one diaminopyridine is pyrimethamine.
14. The use of any one of claims 10 to 13, wherein the bacterial infection is selected from at least one of the group consisting of a gastrointestinal infection, a urogenital infection, a respiratory infection, a skin infection, a systemic infection, a wound infection, and a sexually transmitted infection.
15. The use of any one of claims 10 to 14, wherein the at least one diaminopyridine is or includes an iclaprim.
16. The use of any one of claims 10 to 15, wherein the bacterial infection is considered resistant to one or more of the fosfomycin, the at least one sulfonamide, and the at least one diaminopyridine.
17. The use of any one of claims 10 to 16, wherein in the composition the at least one sulfonamide and the at least one diaminopyridine are in a ratio of between about 3:1 and 6:1.
18. The use of any one of claims 10 to 17, wherein the subject is any of a human, and an animal.
19. The use of any one of claims 10 to 18, wherein the composition is administrable by a route selected from the group consisting of oral, parenteral, topical, ocular, intramuscular, transdermal, nasal, and combinations thereof.
20. A composition for inhibiting growth of a susceptible microorganism, or killing the susceptible microorganism, the composition comprising:
a therapeutically effective amount of the composition, the composition being an antimicrobial, the composition comprising a compingling in a single formulation a combination of at least three components selected from:
a fosfomycin, or a salt, or ester, or an analog, or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism;
a sulfonamide, or a salt, or ester, or an analog or derivative thereof, any of which have inhibitory activity in folic acid metabolism of the susceptible microorganism;
and a diaminopyridine, or a salt, or ester, or an analog, or derivative thereof, any of which inhibit dihydrofolate reductase of the susceptible microorganism, the composition being in a pharmaceutically acceptable form for inhibiting growth of the susceptible microorganism, or killing the susceptible microorganism, and wherein a mean inhibitory concentration of the composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for each of the at least three compounds or agents when the at least three compounds or agents are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least three compounds or agents individually.
a therapeutically effective amount of the composition, the composition being an antimicrobial, the composition comprising a compingling in a single formulation a combination of at least three components selected from:
a fosfomycin, or a salt, or ester, or an analog, or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism;
a sulfonamide, or a salt, or ester, or an analog or derivative thereof, any of which have inhibitory activity in folic acid metabolism of the susceptible microorganism;
and a diaminopyridine, or a salt, or ester, or an analog, or derivative thereof, any of which inhibit dihydrofolate reductase of the susceptible microorganism, the composition being in a pharmaceutically acceptable form for inhibiting growth of the susceptible microorganism, or killing the susceptible microorganism, and wherein a mean inhibitory concentration of the composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for each of the at least three compounds or agents when the at least three compounds or agents are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least three compounds or agents individually.
21. The composition of claim 20, wherein the composition further comprises an excipient.
22. The composition of any one of claim 20 and claim 21, wherein the sulfonamide to diaminopyridine ratio is between about 3:1 and 6:1.
23. The composition of any one of claims 20 to 22, wherein the composition is administered to a subject in need thereof.
24. The composition of any one of claims 20 to 23, wherein the composition is administered to a subject in need thereof in addition to another agent selected from the group consisting of antibiotic, antiviral agent, antifungal agent, anti-parasitic agent, and combinations thereof.
25. The composition of any one of claims 20 to 24, wherein the composition further comprises a carrier to increase an area under a plasma concentration-time curve or AUC of at least one of the three components of the composition after administration of the therapeutically effective amount of the composition to a subject in need thereof, as compared with an AUC of the composition after administration of the therapeutically effective amount of the composition without the carrier.
26. The composition of any one of claims 20 to 25, wherein the composition exhibits an increased area under a plasma concentration-time curve or AUC of at least one of the three components of the composition after administration of the therapeutically effective amount of the composition to a subject in need thereof, as compared with an AUC after administration of the at least one of the three components of the composition alone and at its therapeutically effective amount.
27. The composition of any one of claims 20 to 26, wherein the susceptible microorganism is clinically resistant to at least one of the at least three components.
28. The composition of any one of claims 20 to 27, wherein the susceptible microorganism is a bacteria selected from at least one of Staphylococcus spp., including methicillin-resistant Staphylococcus aureus, Streptococcus spp., Enterococcus spp., Bacillus anthracis, Enterobacteriaceae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkholderia spp., Acinetobacter baumanii, Proteus mirabilis, Proteus vulgaris, Providencia sp., Morganella morganii, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, and Yersinia pestis, and the composition is effective at killing or inhibiting growth of the bacteria.
29. The composition of claim 26, wherein the therapeutically effective amount of the composition includes an amount of at least one of the at least three components that is less than an amount of that component indicated as a therapeutically effective amount when used alone against the susceptible microorganism.
30. An antimicrobial pharmaceutical composition suitable for parenteral injection comprising:
a therapeutically effective amount of a fosfomycin;
a therapeutically effective amount of a sulfonamide; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antimicrobial pharmaceutical composition comprising and comingling at least two of the fosfomycin, the sulfonamide, and the diaminopyridine in a single formulation, the antimicrobial pharmaceutical composition for inhibiting growth of a susceptible microorganism or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when used alone against the susceptible microorganism.
a therapeutically effective amount of a fosfomycin;
a therapeutically effective amount of a sulfonamide; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antimicrobial pharmaceutical composition comprising and comingling at least two of the fosfomycin, the sulfonamide, and the diaminopyridine in a single formulation, the antimicrobial pharmaceutical composition for inhibiting growth of a susceptible microorganism or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when used alone against the susceptible microorganism.
31. The antimicrobial pharmaceutical composition of claim 30, wherein a mean inhibitory concentration of the antimicrobial pharmaceutical composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine, when the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four fold to eight fold below the inhibitory concentration for each of the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine, individually.
32. An antimicrobial fosfomycin composition suitable for oral administration comprising:
a therapeutically effective amount of a fosfomycin;
a therapeutically effective amount of a sulfonamide; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antimicrobial pharmaceutical composition comprising and comingling at least two of the fosfomycin, the sulfonamide, and the diaminopyridine in a single formulation, the antimicrobial pharmaceutical composition for inhibiting growth of a susceptible microorganism or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when the at least one of the fosfomycin, the sulfonamide, and the diaminopyridine is used alone against the susceptible microorganism.
a therapeutically effective amount of a fosfomycin;
a therapeutically effective amount of a sulfonamide; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antimicrobial pharmaceutical composition comprising and comingling at least two of the fosfomycin, the sulfonamide, and the diaminopyridine in a single formulation, the antimicrobial pharmaceutical composition for inhibiting growth of a susceptible microorganism or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when the at least one of the fosfomycin, the sulfonamide, and the diaminopyridine is used alone against the susceptible microorganism.
33. The antimicrobial pharmaceutical composition of claim 32, wherein a mean inhibitory concentration of the antimicrobial pharmaceutical composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine, when the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine, individually.
34. An antimicrobial pharmaceutical composition suitable for inhalation comprising:
a therapeutically effective amount of a fosfomycin;
a therapeutically effective amount of a sulfonamide; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antimicrobial pharmaceutical composition comprising and comingling at least two of the fosfomycin, the sulfonamide, and the diaminopyridine in a single formulation, the antimicrobial pharmaceutical composition for inhibiting growth of a susceptible microorganism or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when the at least one of the fosfomycin, the sulfonamide, and the diaminopyridine is used alone against the susceptible microorganism.
a therapeutically effective amount of a fosfomycin;
a therapeutically effective amount of a sulfonamide; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antimicrobial pharmaceutical composition comprising and comingling at least two of the fosfomycin, the sulfonamide, and the diaminopyridine in a single formulation, the antimicrobial pharmaceutical composition for inhibiting growth of a susceptible microorganism or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, the sulfonamide, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when the at least one of the fosfomycin, the sulfonamide, and the diaminopyridine is used alone against the susceptible microorganism.
35. The antimicrobial pharmaceutical composition of claim 34, wherein a mean inhibitory concentration of the antimicrobial pharmaceutical composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine, when the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the at least two of the fosfomycin, the sulfonamide, and the diaminopyridine, individually.
36. The antibiotic pharmaceutical composition of any one or more of Claims 30 to 35, wherein the infection is a complicated bacterial infection selected from one or more of the group consisting of a complicated urinary tract infection, a complicated respiratory tract infection, including a lung infection associated with cystic fibrosis, hospital acquired bacterial pneumonia, acute exacerbation of bronchitis associated with chronic obstructive pulmonary disease, a ceftriaxone resistant infection, a drug-resistant abdominal infection, and a complicated abdominal infection.
37. An antibiotic pharmaceutical composition comprising in a single formulation at least:
a therapeutically effective amount of a fosfomycin; and a therapeutically effective amount of a sulfonamide, the antibiotic pharmaceutical composition for inhibiting growth of a susceptible microorganism, or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, and the sulfonamide, is less than an amount indicated as a therapeutically effective amount when at least one of the fosfomycin, and the sulfonamide is used alone against the susceptible microorganism.
a therapeutically effective amount of a fosfomycin; and a therapeutically effective amount of a sulfonamide, the antibiotic pharmaceutical composition for inhibiting growth of a susceptible microorganism, or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, and the sulfonamide, is less than an amount indicated as a therapeutically effective amount when at least one of the fosfomycin, and the sulfonamide is used alone against the susceptible microorganism.
38. The antimicrobial pharmaceutical composition of claim 37, wherein a mean inhibitory concentration of the antimicrobial pharmaceutical composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for the fosfomycin, and the sulfonamide, when the fosfomycin, and the sulfonamide are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing, and is at least four-fold to eight-fold below the inhibitory concentration for each of the fosfomycin, and the sulfonamide, individually.
39. An antibiotic pharmaceutical composition comprising in a single formulation at least:
a therapeutically effective amount of a fosfomycin; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antibiotic pharmaceutical composition for inhibiting growth of a susceptible microorganism, or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when at least one of the fosfomycin, and the diaminopyridine is used alone against the susceptible microorganism.
a therapeutically effective amount of a fosfomycin; and a therapeutically effective amount of a diaminopyridine, the diaminopyridine selected from at least one of trimethoprim, pyrimethamine, and iclaprim, the antibiotic pharmaceutical composition for inhibiting growth of a susceptible microorganism, or killing the susceptible microorganism, the susceptible microorganism suspected of causing an infection, the fosfomycin provided as a pharmaceutically acceptable salt, ester, or an analog or derivative thereof, any of which have inhibitory activity in cell wall synthesis of the susceptible microorganism, wherein the therapeutically effective amount of at least one of the fosfomycin, and the diaminopyridine, is less than an amount indicated as a therapeutically effective amount when at least one of the fosfomycin, and the diaminopyridine is used alone against the susceptible microorganism.
40. The antimicrobial pharmaceutical composition of claim 39, wherein a mean inhibitory concentration of the antimicrobial pharmaceutical composition when provided for inhibiting growth of the susceptible microorganism is below a resistance breakpoint identified for the fosfomycin, and the diaminopyridine, when the fosfomycin, and the diaminopyridine are individually and independently provided for inhibiting growth of the susceptible microorganism in vitro, the resistance breakpoint having been identified by at least one of the Clinical Laboratories Standards Institute, and the European Committee on Antimicrobial Susceptibility Testing; and at least four-fold to eight-fold below the inhibitory concentration for each of the fosfomycin, and the diaminopyridine, individually.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462081394P | 2014-11-18 | 2014-11-18 | |
US62/081,394 | 2014-11-18 | ||
US201562104805P | 2015-01-18 | 2015-01-18 | |
US62/104,805 | 2015-01-18 | ||
US201562245095P | 2015-10-22 | 2015-10-22 | |
US62/245,095 | 2015-10-22 | ||
PCT/US2015/061324 WO2016081592A1 (en) | 2014-11-18 | 2015-11-18 | Combination therapy effective against microorganisms, including drug resistant microorganisms |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2968135A1 true CA2968135A1 (en) | 2016-05-26 |
Family
ID=56014503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2968135A Pending CA2968135A1 (en) | 2014-11-18 | 2015-11-18 | Combination therapy effective against microorganisms, including drug resistant microorganisms |
Country Status (6)
Country | Link |
---|---|
US (1) | US10898501B2 (en) |
EP (1) | EP3220920A4 (en) |
CA (1) | CA2968135A1 (en) |
MX (1) | MX2017006476A (en) |
TW (1) | TWI725948B (en) |
WO (1) | WO2016081592A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9345717B2 (en) * | 2013-09-25 | 2016-05-24 | Zavante Therapeutics, Inc. | Method for improving drug treatments in mammals |
TWI725948B (en) | 2014-11-18 | 2021-05-01 | 美商福魯瑞爾Abx公司 | Combination therapy effective against microorganisms including drug resistant microorganisms |
US11925653B2 (en) * | 2021-01-25 | 2024-03-12 | Fleurir Abx, Llc | Combination therapy effective against microorganisms, including drug resistant microorganisms |
US20230398101A1 (en) * | 2022-06-09 | 2023-12-14 | Fleurir Abx Llc | Co-agents as Therapy Against Anaerobic Pathogens |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2181330T1 (en) | 2007-08-31 | 2014-04-30 | Statens Serum Institut | Compositions and means for diagnosing microbial infections |
TWI725948B (en) | 2014-11-18 | 2021-05-01 | 美商福魯瑞爾Abx公司 | Combination therapy effective against microorganisms including drug resistant microorganisms |
-
2015
- 2015-11-18 TW TW104138153A patent/TWI725948B/en active
- 2015-11-18 CA CA2968135A patent/CA2968135A1/en active Pending
- 2015-11-18 MX MX2017006476A patent/MX2017006476A/en unknown
- 2015-11-18 EP EP15860075.9A patent/EP3220920A4/en active Pending
- 2015-11-18 WO PCT/US2015/061324 patent/WO2016081592A1/en active Application Filing
- 2015-11-18 US US15/527,705 patent/US10898501B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2017006476A (en) | 2017-09-12 |
US10898501B2 (en) | 2021-01-26 |
EP3220920A4 (en) | 2018-07-25 |
US20180369259A1 (en) | 2018-12-27 |
TWI725948B (en) | 2021-05-01 |
WO2016081592A1 (en) | 2016-05-26 |
TW201632177A (en) | 2016-09-16 |
EP3220920A1 (en) | 2017-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11529361B2 (en) | Halogenated salicylanilides for treating Clostridium infections | |
CN107108624B (en) | Combination therapy for the treatment of drug resistant bacterial infections | |
JP7245289B2 (en) | Methods of treating bacterial infections | |
KR102226197B1 (en) | Ceftolozane antibiotic compositions | |
US10898501B2 (en) | Combination therapy effective against microorganisms, including drug resistant microorganisms | |
US11951148B1 (en) | Pristinamycin compositions, LpxC compositions, their improvements, and combinations thereof | |
KR20140053901A (en) | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor | |
RU2524665C2 (en) | Ceftaroline-including compositions and methods of treatment | |
US10758529B2 (en) | Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity | |
CA2826192A1 (en) | Methods and compositions for treating bacterial infections with iron chelators | |
JP2023012538A (en) | Methods of treating bacterial infections | |
US11925653B2 (en) | Combination therapy effective against microorganisms, including drug resistant microorganisms | |
KR101850265B1 (en) | Compositions comprising antibacterial agent and tazobactam | |
KR102417756B1 (en) | antibacterial composition | |
KR20180125374A (en) | Antimicrobial compositions and methods | |
Afifi et al. | Effect of Paracetamol on the Pharmacokinetics of Cephalexin in Dogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |
|
EEER | Examination request |
Effective date: 20201118 |